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1. Abstract/Riassunto	  
1.1	  Abstract	  
BACKGROUND:	  Malignant	  pleural	  mesothelioma	  (MPM)	  is	  an	  aggressive	  tumor	  
with	   increasing	   incidence	   in	   industrialized	   countries,	   because	   of	   previous	  
widespread	   asbestos	   exposure	   and	   long	   latency	   time	   before	   symptoms	  
appearance.	   Tumor	   necrosis	   factor-­‐related	   apoptosis-­‐inducing	   ligand	   (TRAIL)	  
belongs	   to	   the	   tumor	   necrosis	   factor	   (TNF)	   family	   of	   death	   ligands;	   it	   was	  
identified	   as	   a	   promising	   anticancer	   agent	   thanks	   to	   its	   property	   of	   killing	  
cancer	   cells	   while	   sparing	   normal	   cells.	   Conflicting	   evidences	   about	   MPM	  
resistance	   rather	   than	   sensitivity	   to	   TRAIL-­‐induced	   apoptosis	  were	   previously	  
reported.	  While	  TRAIL-­‐dependent	  apoptosis	  is	  thought	  to	  be	  p53-­‐independent,	  
p53	  wild	  type	  cancer	  cells	  can	  be	  sensitized	  to	  TRAIL	  through	  p53	  activation.	  In	  
contrast	   to	   most	   solid	   tumors,	   MPM	   cells	   frequently	   express	   wild	   type	   p53,	  
thus	  p53	  reactivation	  might	  be	  considered	  as	  an	  effective	  strategy	  to	  sensitize	  
MPM	   cells	   to	   TRAIL-­‐dependent	   apoptosis.	   DNA-­‐damaging	   agents	   such	   as	  
chemotherapy	  or	  radiotherapy	  and	  other	  agents	  targeting	  negative	  regulators	  
of	   p53,	   may	   be	   considered	   as	   useful	   strategies	   to	   reactivate	   p53.	   Murine	  
Double	   Minute	   2	   (MDM2)	   is	   a	   transcriptional	   target	   of	   p53:	   once	   activated,	  
MDM2	   binds	   p53	   to	   the	   amino-­‐terminus,	   targeting	   it	   for	   ubiquitylation	   and	  
subsequent	   proteasomal	   degradation.	   Recently,	   many	   researchers	   have	  
investigated	   a	   possible	   role	   of	   MDM2	   in	   promoting	   tumor	   neoangiogenesis	  
(Vascular	   Endothelial	   Growth	   Factor,	   VEGF;	   hypoxia	   inducible	   factor,	  
HIF1alpha).	  Thus	  MDM2	  might	  be	  a	  promising	  target	  for	  anticancer	  treatment	  
because	   of	   its	   antiapoptotic	   and	   proangiogenetic	   role.	   The	   poor	   prognosis	   of	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affected	   patients,	   the	   lack	   of	   effective	   treatment	   options,	   with	   particular	  
reference	   to	   biologic	   drugs,	   the	   absence	   of	   predictive	   markers	   for	   targeted	  
treatment	  and	  the	  lack	  of	  knowledge	  about	  the	  basis	  of	  different	  biological	  and	  
clinical	  behaviour	  of	  the	  two	  main	  histologic	  subtypes,	  epithelioid	  versus	  non-­‐
epithelioid	   (sarcomatoid/biphasic),	   constitute	   the	   rationale	   for	   the	   present	  
study.	  
AIMS:	  The	  first	  purpose	  of	  the	  study	  was	  to	  investigate	  new	  treatment	  options	  
through	   preclinical	   evaluation	   of	   extrinsic	   apoptosis	   triggers	   (recombinant	  
human	   Apo2L/TRAIL)	   in	   combination	   with	   intrinsic	   apoptosis	   inducers	   acting	  
through	   the	   reactivation	   of	   p53,	   such	   as	   DNA-­‐damaging	   agents	  
(carboplatin/pemetrexed)	   or	   p53-­‐MDM2	   inhibitors	   (nutlin3-­‐RG7112),	   both	   in	  
vitro	  and	  in	  vivo.	  Moreover,	  the	  study	  aims	  to	  investigate	  new	  targets	  (MDM2,	  
HIF1alpha,	   VEGF)	   for	   treatment	   in	   MPM	   tumor	   samples,	   testing	   possible	  
different	  expression	   levels	  of	  such	  targets	   in	  the	  different	  histologic	  subtypes.	  
Some	  morphological	  features,	  such	  as	  inflammation,	  necrosis	  and	  proliferation	  
were	   quantified	   in	   the	   different	   histotypes	   and	   correlated	   with	   MDM2	   and	  
HIF1alpha.	   Finally,	   correlations	   between	  molecular	   data	   and	   clinical	   features	  
were	  performed.	  
METHODS:	   Anticancer	   effects	   of	   rhApo2L/TRAIL	   (Amgen,	   Genentech)	   plus	  
chemotherapy	   (Carboplatin/Pemetrexed)	   or	   nutlin3-­‐RG7112	   (Roche)	   was	  
evaluated	  in	  different	  cell	  lines	  through	  annexin	  V	  and	  caspases	  assay,	  and	  in	  a	  
Severe	   Combined	   ImmunoDeficiency	   (SCID)	   mouse	   model.	   p53	   expression	  
levels	  were	   evaluated	   through	  western	   blot.	   TRAIL	   receptors	  were	   evaluated	  
through	  flow	  cytometry.	  Formalin-­‐Fixed	  Paraffin	  Embedded	  (FFPE)	  chemonaive	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tumor	  samples	  from	  MPM	  patients	  were	  analyzed:	  MDM2,	  VEGF	  and	  HIF1alpha	  
mRNA	   and	   protein	   expression	   levels	  were	   investigated	   through	   RT-­‐qPCR	   and	  
immunohistochemistry	  (IHC)	  with	  specific	  antibodies,	  respectively.	  Proliferation	  
was	   quantified	   through	   staining	   with	   Ki67	   antibodies.	   Necrosis	   and	  
inflammation	   were	   also	   quantified	   on	   histological	   sections	   using	   a	   grading	  
score.	  Normal	  pleura	  samples	  from	  patients	  undergoing	  diagnostic	  surgery	  for	  
non	  cancer	  disease	  were	  used	  as	  negative	  controls.	  Clinical	  data	  of	  the	  patients	  
under	   study	   were	   collected	   in	   a	   password-­‐protected	   database:	   age,	   gender,	  
ECOG	   PS	   (Performance	   Status),	   EORTC	   score,	   stage,	   systemic	   treatments,	  
surgery,	   radiotherapy,	   first	   progression	   and	   last	   follow-­‐up	   date,	   status	  
(alive/dead).	  
RESULTS:	  In	  vitro	  and	  in	  vivo	  results	  showed	  a	  significant	  increase	  of	  apoptosis	  
in	   cell	   lines	   and	   reduction	   of	   tumor	   volume	   in	   animal	   models	   treated	   with	  
rhApo2L/TRAIL	   plus	   chemotherapy	   or	   nutlin3-­‐RG7112	   compared	   with	   those	  
receiving	  single	  treatments.	  This	  synergistic	  effect	  was	  dependent	  on	  the	  ability	  
of	   chemotherapy	   or	   nutlin3-­‐RG7112	   to	   increase	   the	   expression	   of	   the	   TRAIL	  
receptors	   DR4	   and	   DR5	   in	   a	   p53	   manner.	   Higher	   MDM2	   and	   HIF1alpha	   IHC	  
expression	   was	   significantly	   associated	   with	   sarcomatoid/biphasic	   histologic	  
subtype	  (p=0.010	  and	  p=0.007,	  respectively)	  with	  positive	  correlation	  	  between	  
MDM2	  and	  HIF1alpha	  expression	  levels	  (correlation	  coefficient=0.533;	  p	  value=	  
0.00626).	   Proliferation	   index	   was	   significantly	   higher	   in	   sarcomatoid/biphasic	  
compared	   with	   epithelioid	   samples	   (p=0.005)	   and	   also	   significantly	   higher	   in	  
tumor	   samples	   with	   higher	   MDM2	   expression	   (p=0.008).	   Clinical	   and	  
pathological	   features	   or	   biomarker	   did	   not	   show	   any	   correlation	   with	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prognosis,	   except	   for	   proliferation	   index	   and	   Progression	   Free	   Survival	   (PFS),	  
even	  though	  the	  results	  of	  this	  exploratory	  analysis	  should	  be	  considered	  with	  
caution	   because	   of	   the	   limited	   number	   of	   patients,	   the	   heterogeneous	  
treatment	  received	  and	  the	  insufficient	  follow-­‐up	  time	  in	  some	  patients.	  	  
CONCLUSION:	   Our	   preclinical	   in	   vitro	   and	   in	   vivo	   results	   confirm	   that	  
reactivation	   of	   p53	   by	   chemotherapy	   or	   p53-­‐MDM2	   inhibitors	   effectively	  
sensitizes	  to	  TRAIL-­‐dependent	  apoptosis	  in	  malignant	  pleural	  mesothelioma.	  
Our	   translational	   study	   in	   tumor	   samples	   from	   MPM	   patients	   confirmed	  
different	  biological	  and	  pathological	  features	  and	  molecular	  targets	  expression	  
in	  the	  two	  main	  histologic	  subtypes.	  It	  is	  tempting	  to	  speculate	  that	  MDM2	  and	  
Ki67	   might	   be	   considered	   as	   further	   useful	   diagnostic	   tools	   to	   identify	   poor	  
prognosis	   patients.	  Moreover,	  MDM2	   and	   HIF1alpha	  might	   be	   considered	   as	  
promising	  targets	  for	  anticancer	  treatment	  of	  MPM.	  
1.2	  Riassunto	  
BACKGROUND:	   Il	   mesotelioma	   pleurico	   maligno	   (MPM)	   è	   una	   neoplasia	  
aggressiva	  con	   incidenza	   in	  aumento	  nei	  paesi	   industrializzati	  per	   la	  pregressa	  
esposizione	   ad	   amianto	   e	   il	   lungo	   periodo	   di	   latenza	   tra	   l’esposizione	   e	   la	  
comparsa	  dei	  sintomi.	  TRAIL	  (Tumor	  necrosis	  factor-­‐related	  apoptosis-­‐inducing	  
ligand)	   appartiene	  alla	   famiglia	  dei	   ligandi	  di	  morte	  apoptotica	  di	   TNF	   (tumor	  
necrosis	   factor),	   ed	   è	   stato	   recentemente	   identificato	   come	   promettente	  
agente	  antitumorale	  in	  considerazione	  della	  sua	  proprietà	  di	  uccidere	  le	  cellule	  
tumorali,	   risparmiando	   le	   cellule	   normali.	   Evidenze	   contrastanti	   riportano	   la	  
presenza	  di	   resistenza	  piuttosto	  che	  di	  sensibilità	  delle	  cellule	  di	  mesotelioma	  
maligno	  all’apoptosi	  mediata	  da	  TRAIL.	  Sebbene	  l’apoptosi	  indotta	  da	  TRAIL	  (via	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estrinseca	   dell’apoptosi)	   sembra	   essere	   indipendente	   da	   p53,	   alcune	   cellule	  
tumorali	  portatrici	  di	  p53	  wild-­‐type	  possono	  essere	  sensibilizzate	  alla	  morte	  da	  
TRAIL	   attraverso	   l’attivazione	   di	   p53	   (via	   intrinseca	   dell’apoptosi).	  
Contrariamente	   alla	  maggior	   parte	   delle	   neoplasie,	   le	   cellule	   di	  mesotelioma	  
pleurico	  esprimono	  più	  frequentemente	  p53	  wild-­‐type,	  e	  quindi	  la	  riattivazione	  
di	   p53	   potrebbe	   essere	   una	   strategia	   efficace	   per	   sensibilizzare	   le	   cellule	   di	  
mesotelioma	  all’apoptosi	  mediata	  da	  TRAIL.	  Agenti	   in	   grado	  di	   danneggiare	   il	  
DNA	  (chemioterapia,	   radioterapia)	  ed	  altri	  agenti	   in	  grado	  di	  “down-­‐regolare”	  
gli	   inibitori	   di	   p53,	   possono	   essere	   considerati	   come	   valide	   strategie	   per	  
riattivare	   p53.	   Murine	   Double	   Minute	   2	   (MDM2)	   è	   un	   bersaglio	   dell’attività	  
trascrizionale	   di	   p53:	   una	   volta	   attivata,	   MDM2	   lega	   il	   dominio	   ammino-­‐
terminale	   di	   p53	   e	   la	   conduce	   al	   processo	   di	   ubiquitilazione	   e	   successiva	  
degradazione	  proteasomica.	  Negli	  anni	  recenti,	  molti	  ricercatori	  hanno	  studiato	  
un	   possibile	   ruolo	   di	  MDM2	   nella	   attivazione	   di	  marcatori	   di	   neoangiogenesi	  
tumorale	  (Vascular	  Endothelial	  Growth	  Factor,	  VEGF;	  hypoxia	  inducible	  factor,	  
HIF1alpha),	  pertanto	  MDM2	  potrebbe	  rappresentare	  un	  promettente	  bersaglio	  
per	   il	   trattamento	   antitumorale	   in	   considerazione	   della	   sua	   possibile	   duplice	  
attività	   antiapoptotica	   e	   proangiogenetica.	   La	   prognosi	   infausta	   dei	   pazienti	  
affetti,	   l’assenza	   di	   opzioni	   terapeutiche	   efficaci,	   in	   particolare	   di	   farmaci	  
biologici,	   l’assenza	   di	   marcatori	   predittivi	   di	   risposta	   ai	   farmaci	   a	   bersaglio	  
molecolare,	   e	   la	   scarsità	   di	   conoscenze	   sui	   meccanismi	   che	   sottendono	   al	  
diverso	  comportamento	  biologico	  e	  clinico	  dei	  due	  principali	  sottotipi	  istologici	  
(epitelioide	   versus	   non-­‐epitelioide),	   costituiscono	   il	   razionale	   del	   presente	  
studio.	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OBIETTIVI:	   Il	   primo	   obiettivo	   è	   stato	   valutare	   nuove	   opzioni	   terapeutiche	  
attraverso	  studi	  preclinici	   in	  vitro	  ed	   in	  vivo	  con	  associazione	  di	   induttori	  della	  
via	   estrinseca	   dell’apoptosi	   (rhApo2L/TRAIL)	   e	   induttori	   della	   via	   intrinseca	  
dell’apoptosi	   che	   agiscono	   attraverso	   riattivazione	   di	   p53,	   come	   agenti	  
danneggianti	   il	   DNA	   (carboplatino/pemetrexed)	   o	   inibitori	   del	   legame	   p53-­‐
MDM2	  (nutlin3-­‐RG7112).	  Secondariamente,	  lo	  studio	  si	  è	  proposto	  di	  ricercare	  
l’espressione	   dei	   nuovi	   bersagli	   terapeutici	   (MDM2,	   HIF1alpha)	   nei	   campioni	  
tumorali	   di	   pazienti	   affetti	   da	  mesotelioma	  maligno,	   e	   di	   valutarne	   la	   diversa	  
espressione	   nei	   diversi	   sottotipi	   istologici.	   Inoltre,	   il	   progetto	   si	   è	   focalizzato	  
sulla	  valutazione	  di	  alcuni	  parametri	  morfologici	  come	   infiammazione,	  necrosi	  
ed	   indice	   proliferativo	   nei	   campioni	   tumorali	   dei	   diversi	   istotipi	   e	   sulla	   loro	  
correlazione	  con	  MDM2	  e	  HIF1alpha.	  Infine,	  sono	  state	  valutate	  le	  correlazioni	  
tra	  dati	  molecolari	  e	  caratteristiche	  cliniche	  dei	  pazienti	  in	  studio.	  	  
MATERIALI	   E	   METODI:	   l’attività	   antitumorale	   di	   rhApo2L/TRAIL	   (Amgen,	  
Genentech)	   in	   associazione	   a	   chemioterapia	   (Carboplatino/Pemetrexed)	   o	  
nutlin3-­‐RG7112	   (Roche)	   è	   stata	   valutata	   in	   diverse	   linee	   cellulari	   attraverso	   il	  
saggio	  di	  Annessina	  V	  e	  delle	  caspasi,	  e	  in	  un	  modello	  di	  topo	  Severe	  Combined	  
ImmunoDeficiency	   (SCID).	   I	   livelli	   di	   espressione	   di	   p53	   sono	   stati	   analizzati	  
attraverso	   western	   blot.	   I	   recettori	   di	   TRAIL	   sono	   stati	   rilevati	   attraverso	  
citofluorimetria.	  Campioni	  tumorali	  fissati	  in	  formalina	  e	  inclusi	  in	  paraffina	  da	  
pazienti	  chemonaive	   sono	   stati	   analizzati	   con	   immunoistochimica	  e	  valutando	  
l’espressione	   di	   mRNA	   per	   MDM2	   e	   HIF1alpha.	   L’indice	   proliferativo	   è	   stato	  
quantificato	   mediante	   anticorpo	   monoclonale	   di	   Ki67.	   La	   presenza	   di	  
infiammazione	   e	   necrosi	   è	   stata	   valutata	   su	   sezioni	   istologiche.	   Campioni	   di	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pleura	   normale	   da	   pazienti	   sottoposti	   a	   chirurgia	   toracica	   per	   patologia	   non	  
oncologica	  sono	  stati	  utilizzati	  come	  controlli	  negativi.	  I	  dati	  clinici	  dei	  pazienti	  
in	  studio	  sono	  stati	   raccolti	  un	  un	  database	  protetto	  da	  password:	  età,	   sesso,	  
ECOG	   PS	   (Performance	   Status),	   score	   prognostico	   EORTC,	   stadio,	   trattamenti	  
sistemici,	  chirurgia,	  radioterapia,	  prima	  progressione,	  data	  di	  ultimo	  follow-­‐up	  
e	  status	  (vivo/morto).	  	  
RISULTATI:	   I	   risultati	   in	   vitro	   ed	   in	   vivo	  mostrano	  un	   significativo	   aumento	  di	  
apoptosi	   in	   linee	   cellulari	   e	   riduzione	   di	   volume	   tumorale	   in	   modelli	   animali	  
trattati	  con	  rhApo2L/TRAIL	   in	  associazione	  a	  chemioterapia	  o	  nutlin3-­‐RG7112,	  
confrontato	   ai	   singoli	   trattamenti.	   Tale	   effetto	   sinergico	   è	   correlato	  
all’incremento	  di	  espressione	  dei	  recettori	  di	  TRAIL	  (DR4	  e	  5)	  conseguente	  alla	  
riattivazione	  di	  p53	  da	  chemioterapia	  o	  nutlin3-­‐RG7112.	  Abbiamo	  poi	  valutato	  i	  
livelli	  di	  espressione	  di	  MDM2	  e	  del	  suo	  possibile	  target	  HIF1alpha	  in	  campioni	  
tumorali	  di	  pazienti	  affetti	  da	  mesotelioma.	   I	   livelli	  di	  espressione	  di	  MDM2	  e	  
HIF1alpha	   erano	   significativamente	   più	   elevati	   nel	   sottotipo	   istologico	  
sarcomatoide/bifasico	   (p=0.010	   and	   p=0.007,	   respectively),	   ed	   è	   stata	  
osservata	   una	   correlazione	   positiva	   tra	   i	   livelli	   di	   espressione	   di	   MDM2	   e	  
HIF1alpha	   (coefficiente	   di	   correlazione	   =0.533;	   p	   =	   0.00626).	   Infine,	   l’indice	  
proliferativo	  (Ki67)	  si	  è	  dimostrato	  significativamente	  più	  elevato	  nel	  sottotipo	  
istologico	   sarcomatoide/bifasico	   rispetto	   a	   quello	   epitelioide	   (p=0.005)	   e	  
significativamente	   più	   elevato	   nei	   campioni	   con	   iperespressione	   di	   MDM2	  
(p=0.008).	   Per	   quanto	   riguarda	   gli	   obiettivi	   esploratori	   del	   progetto,	   nessuna	  
correlazione	   prognostica	   è	   stata	   osservata	   per	   alcun	   parametro	   clinico	   o	  
patologico	  o	  per	  diversi	  livelli	  di	  espressione	  dei	  biomarcatori	  in	  studio,	  mentre	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è	   stata	   osservata	   una	   correlazione	   significativa	   tra	   i	   livelli	   di	   Ki67	   e	   la	  
sopravvivenza	   libera	   da	   progressione.	   I	   risultati	   di	   tale	   indagine	   esploratoria	  
devono,	  comunque,	  essere	  considerati	   con	  cautela	  per	   la	   limitata	  dimensione	  
campionaria,	   l’eterogeneità	  degli	   interventi	  terapeutici	  e	   l’insufficiente	  follow-­‐
up	  di	  alcuni	  pazienti.	  
CONCLUSIONI:	   I	   risultati	   in	   vitro	   e	   in	   vivo	   di	   questo	   progetto	   di	   ricerca	  
dimostrano	  che	   la	   riattivazione	  di	  p53	  con	  chemioterapia	  o	  molecole	   inibitrici	  
del	   legame	   p53-­‐MDM2	   rappresenta	   un’efficace	   strategia	   per	   sensibilizzare	  
all’apoptosi	   mediata	   da	   TRAIL.	   Lo	   studio	   traslazionale	   ha	   invece	   confermato	  
diverse	   caratteristiche	   biologiche	   e	   patologiche	   così	   come	   differenti	   livelli	   di	  
espressione	   di	   nuovi	   bersagli	   terapeutici	   nei	   due	   sottotipi	   istologici	   di	  MPM.	  
MDM2	  e	  Ki67	  possono	  essere	  considerati	  come	  importanti	  ausili	  diagnostici	  per	  
una	   migliore	   caratterizzazione	   dell’istotipo	   e	   soprattutto	   per	   identificare	   i	  
tumori	   a	   peggiore	   prognosi.	   Inoltre,	   MDM2	   e	   HIF1alpha	   potrebbero	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2. Background	  
2.1 Malignant	  Pleural	  Mesothelioma	  
Malignant	  Pleural	  Mesothelioma	   (MPM)	   is	   an	   aggressive	   cancer	   involving	  
pleural	  surfaces	  and,	  in	  the	  advanced	  stage,	  lung	  parenchyma,	  leading	  to	  a	  
typicale	  clinical	  picture	  characterized	  by	  chest	  pain,	  dyspnoea	  and	  cough.	  
Although	   the	  main	   risk	   factor	   is	   asbestos	   exposure,	   other	   factors	   have	   a	  
central	   role	   in	   MPM	   pathogenesis.	   The	   biological	   behaviour	   of	   MPM	   is	  
determined	  by	  molecular	   alterations,	   such	   as	   oncosuppressor	   genes	   loss,	  
like	  p16INK4A	  and	  p14ARF,	  while	  rare	  mutations	  or	  deletions	  of	  p53	  and	  pRb,	  
which	   are	   commonly	   involved	   in	   the	   pathogenesis	   of	   most	   cancer.	   Such	  
molecular	  aberrations	  seem	  to	  be	  the	  basis	  of	  MPM	  resistance	  to	  systemic	  
treatments	  currently	  adopted	  in	  the	  medical	  management	  of	  this	  disease.	  
Surgery	   is	   feasible	   only	   in	   selected	   cases	   and	   current	   gold	   standard	  
chemotherapy	  in	  unresectable	  disease	  is	  a	  platinum-­‐based	  doublet	  with	  an	  
antifolate	   agent,	   which	   shows	   a	   median	   overall	   and	   progression	   free	  
survival	   of	   approximately	   12	   and	   6	  months	   respectively,	   and	   a	   response	  
rate	  of	  20-­‐40%[1,	  2]	  	  
High	   refractoriety	   to	   systemic	   treatment,	   rare	   and	   short-­‐term	   complete	  
responses	  make	  MPM	  a	  therapeutic	  challenge.	  Improved	  knowledge	  about	  
molecular	   pathways	   lead	   to	   several	   clinical	   trials	   investigating	   biologic	  
agents	   in	   the	   treatment	   of	   MPM,	   even	   though	   they	   have	   not	   found	   a	  
precise	  placement	  in	  the	  therapeutic	  strategy	  yet.	  
2.1.1.	  Epidemiology	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The	   incidence	   of	   MPM	   shows	   some	   difference	   among	   countries,	   and	  
epidemiologic	   data	   are	   somewhere	   lacking.	   Whereas	   in	   some	   countries	  
MPM	  and	  cancer	   registers	  are	  available,	   in	  other	   countries	   few	  areas	  are	  
covered	   with	   sufficient	   information	   and	   relative	   rates	   are	   estimated	   by	  
mortality	  data;	  elsewhere,	  only	  surveys	  of	  medical	  doctors	  and	  researchers	  
are	  available.	  Such	  heterogeneous	  picture	  determines	  that	  not	  all	  available	  
data	  have	  the	  same	  reliability.	  	  
In	   most	   European	   countries,	   such	   as	   France,	   Germany,	   Italy	   and	  
Scandinavia,	   the	   incidence	   rate	   is	  between	  11	  and	  20	  cases	  on	  1.000.000	  
inhabitants[3],	  and	  these	  rates	  may	  vary	  about	  70	   times	  according	   to	   the	  
geographical	   area.	   In	   Italy,	   the	  National	  Mesothelioma	   Register	   (Registro	  
Nazionale	   Mesotelioma,	   ReNaM)	   reports	   an	   incidence	   of	   2.98	   and	   0.98	  
(rough	   rates,	   on	   100.000	   inhabitants,	   per	   year)	   in	   males	   and	   females,	  
respectively.	  	  
Analysis	   on	   asbestos	   exposure	   and	  MPM	   incidence	   performed	   in	   several	  
industrialized	   countries,	   showed	   a	   statistically	   significant	   correlation	  
between	   the	   two	   variables[4,	   5].	   At	   the	   national	   level,	   the	   geographic	  
distribution	  of	  MPM	  reflects	  the	  location	  of	  industries	  using	  asbestos	  such	  
as	   shipyards,	   building	   construction,	   production	   of	   asbestos	   cement	   and	  
construction/repair	   of	   railway	   cars;	   in	   Italy,	   mortality	   data	   for	   pleural	  
cancer	  in	  males,	  between	  1988	  and	  1997,	  showed	  wide	  variations	  between	  
one	   province	   and	   another.	   Higher	   mortality	   rates,	   between	   4	   and	  
12/100.000,	   are	   shown	   in	   ares	   where	   the	   main	   shipyards	   and	   cement	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factories	   are	   located.	   Among	   the	   most	   affected	   provinces,	   Casale	  
Monferrato,	  Savona,	  Genova,	  La	  Spezia,	  Alessandria,	  Gorizia	  and	  Trieste.	  	  
In	   Italy	   the	  extraction,	   import	  and	  marketing	  of	  asbestos	  were	  banned	   in	  
1992	  but	  due	  to	  the	  long	  lag	  time	  (even	  40	  years)	  from	  exposure	  to	  clinical	  
evidence	   of	   MPM	   the	   epidemiologic	   data	   foresee	   a	   sharp	   rise	   of	   MPM	  
incidence	   and	   mortality	   in	   the	   next	   fifteen	   years[6].	   European	  
epidemiological	   surveys	   foresee	   the	   mortality	   peak	   for	   MPM	   in	   males	  
between	  2015	  and	  2020	  [7],[8,	  9].	  
The	  Veneto	  region	  is	  particularly	  interested	  by	  asbestos	  exposure	  because	  
of	   its	  strong	   industrial	  development.	   Incidence	   is	  about	  2.3/100.000/year,	  
quite	   superior	   to	   the	  mean	  national	  and	  European	   incidence.	  Since	  1987,	  
about	   2000	   new	   cases	   of	   malignant	   pleural	   mesothelioma	   have	   been	  
registered,	  with	  mean	  incidence	  over	  80	  new	  cases/year.	  Most	  of	  them	  are	  
males	   with	   a	   previous	   occupational	   exposure,	   but	   many	   females	   living	  
close	   to	   some	   industries	   or	   with	   asbestos	   exposed	   workers	   are	   also	  
affected.	   Thus	   malignant	   mesothelioma	   has	   a	   strong	   social	   impact	   that	  
deserves	  attention	  by	  the	  National	  Health	  Service	  (NHS).	  
2.1.2	  Etiology	  and	  pathogenesis	  	  
Etiopathogenesis	   of	  MPM	   is	   attributable	   in	   80%	  of	   the	   cases	   to	   asbestos	  
exposure.	  Asbestos	   fibers	   are	   classified	   in	   two	  main	   groups,	   according	   to	  
size	   and	   bio-­‐persistance:	   serpentine	   (chrysotile)	   and	   amphibole	  
(crocidolite,	   tremolite,	   anthofillite	   and	   amosite).	   Even	   if	   in	   the	   different	  
experimental	   models	   all	   asbestos	   fibers	   have	   shown	   cancerogenetic	  
potential[10],	  subsequent	  evidence	  confirm	  a	  weak	  potential	  of	  chrysotile	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fibers[11],	   and	   currently	   the	   scientific	   community	   agree	   on	   a	   higher	  
cancerogenetic	  potential	  of	   thinner	  and	   longer	  asbestos	   fibers	  and	  of	   the	  
subtypes	  amphibole,	  compared	  to	  shorter	  and	  chrisotile	  fibers.	  
Asbestos	  fibers	  may	  directly	  damage	  the	  DNA	  of	  mesothelial	  cells,	  by	  laying	  
down	  and	  penetrating	  in	  the	  pleura,	  and	  leading	  to	  a	  process	  characterized	  
by	   damage,	   repair	   and	   local	   inflammation,	   pleural	   plaques	   or	  
mesothelioma.	  Another	  mechanism	   implied	   in	  asbestos	   cancerogenesis	   is	  
the	   reactive	   oxygen	   species	   (ROS)	   and	   cytokines	   production	   by	  
macrophages[12],	   which	   determine	   DNA	   damage	   and	   an	  
immunocompromised	  state.	  Moreover,	  asbestos	  fibers	  are	  able	  to	  interfer	  
with	  mitotic	  processes,	  inducing	  aneuploidy	  and	  chromosomal	  aberrations,	  
and	   to	   activate	   some	   kinases	   such	   as	   MAPK	   (mitogen-­‐activated	   protein	  
kinase)and	  ERK1	  and	  2	  (extracellular	  signal-­‐regulated	  kinases	  1	  and	  2)[13].	  
The	  complex	  cancerogenetic	  process	  leading	  to	  plural	  mesothelioma	  might	  
be	   triggered	   by	   other	   factors	   such	   as	   genetics,	   ionizing	   radiations,	   SV40	  
virus	  (Simian	  Virus	  40)	  [14].	  
Loss	  of	  heterozygosity	   (LOH)	   is	  a	   frequent	  process	   in	   the	  pathogenesis	  of	  
MPM,	  and	  the	  result	   is	   the	   loss	  or	   inactivation	  of	  several	  oncosuppressor	  
genes.	  	  
Even	   though	   mutation	   and	   deletion	   of	   p53	   and	   pRb	   tumour	   suppressor	  
genes	  occur	  frequently	  in	  a	  lot	  of	  human	  cancers,	  they	  are	  extremely	  rare	  
in	   malignant	   mesothelioma[15]	   Probably,	   a	   functional	   apoptotic	   defect	  
causing	   MPM	   resistance	   to	   chemotherapy	   and	   radiotherapy	   occurs	  
downstream	  p53	  and	  pRb.	  The	  INK4a/ARF	  locus	  within	  9p21	  chromosome	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encodes	   two	   proteins,	   p16INK4a	   	   and	   p14ARF	   ,	   and	   previous	   series	  
demonstrated	   deletion	   of	   this	   genome	   region	   in	   70%	   of	  MPM	   cell	   lines.	  
p16INK4a	   	   inhibits	   cyclinD-­‐dependent	   kinase	   (CDK),	   preventing	   the	  
phosphorilation	   and	   subsequent	   inactivation	   of	   pRb,	   whereas	   p14	  
promotes	   the	   degradation	   of	  Murine	   Double	  Minute	   2	   (MDM2)	   protein,	  
that	   is	   responsible	   for	   p53	   ubiquitination	   and	   inactivation.	   p53	   leads	   the	  
cell	   to	  apoptosis	  or	   inhibits	   the	  entrance	   into	   the	  cell	   cycle,	  whereas	  pRb	  
arrests	  the	  cell	  in	  G1	  phase	  (see	  section	  2.2.2).	  
The	  most	  frequent	  chromosomal	  aberration	  in	  MPM	  is	  on	  chromosome	  22,	  
where	  the	  oncosuppressor	  gene	  NF2	  (Neurofibromatosis	  2)	   is	   located	  and	  
the	  protein	  merlin	  is	  encoded.	  Mutations	  of	  NF2	  gene	  have	  been	  observed	  
in	   40%	   of	  MPM	   cases[16-­‐18].	   In	   animal	   models	   with	   asbestos	   exposure,	  
MPM	   is	   most	   commonly	   observed	   after	   inactivation	   of	   one	   NF2	   allele,	  
compared	   to	  wild	   type;	  moreover,	   the	   other	   allele	   is	   often	   loss	   in	  MPM,	  
thus	  confirming	  its	  role	  as	  a	  gatekeeper[19,	  20].	  The	  loss	  of	  the	  remaining	  
allele	  is	  often	  associated	  with	  the	  loss	  of	  INK4a/ARF	  locus,	  which	  might	  be	  
responsible	  for	  a	  ‘permissive’	  background.	  
The	   BCL2	   family	   of	   genes	  which	   regulate	   the	   apoptotic	   process	   plays	   an	  
important	   role	   in	   the	   cancerogenesis	   process;	   this	   family	   includes	  
proapoptotic	   genes	   such	   as	   BAX,	   BAK	   and	   BAD,	   and	   antiapoptotic	   genes	  
such	   as	   BCL2,	   BCLXL,	   MCL1.	   BCL2	   is	   rarely	   expressed	   in	   MPM,	   but	   high	  
mRNA	  levels	  of	  BCLXL	  have	  been	  observed	  in	  MPM	  cell	  lines	  and	  in	  tumor	  
tissue	  samples	  [21-­‐23],	  probably	  in	  order	  to	  contrast	  with	  the	  proapoptotic	  
effect	  of	  BAX,	  expressed	  in	  MPM	  cell	  lines[15].	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Many	  growth	  factors	  play	  a	  role	  in	  the	  pathogenesis	  of	  MPM,	  such	  as	  IGF-­‐1	  
(Insulin-­‐like	  growth	  factor-­‐1),	  HGF	  (hepatocyte	  growth	  factor),	  bFGF	  (basic	  
fibroblast	   growth	   factor),	   EGF	   (epidermal	   growth	   factor),	   VEGF	   (vascular	  
endothelial	  growth	  factor),	  PDGF	  A	  e	  B	  (platelet-­‐derived	  growth	  factor	  A	  e	  
B),	  TNF	  (tumor	  necrosis	   factor).	  These	  factors	  come	  from	  the	  surrounding	  
lung	   parenchyma,	   macrophages	   or	   mesothelial	   cells,	   after	   different	  
stimula,	  inflammatory	  cytochines,	  asbestos,	  SV40	  infection.	  Growth	  factors	  
promote	   tumor	   growth,	   proliferation	   and	   invasiveness,	   but	   also	   the	  
neoangiogenesis	  process	  which	  feeds	  the	  growing	  tumor	  with	  oxygen	  and	  
metabolites	  (see	  section	  2.3).	  
2.1.3	  Histopathologic	  and	  clinical	  features	  and	  treatment	  
MPM	  usually	  arises	  between	  the	  fifth	  and	  seventh	  decade,	  more	  frequently	  
in	  males	  (males:females	  equal	  to	  3-­‐5:1).	  Affected	  patients	  tipically	  come	  to	  
the	   medical	   evaluation	   with	   pleural	   effusion	   (80%),	   and	   subsequent	  
symptoms	  such	  as	  chest	  pain	  (60%)	  and	  exercise	  dyspnoea	  (50-­‐70%).	  Other	  
symptoms	  such	  as	  weight	   loss	  and	  fatigue	  might	  be	  present,	  especially	   in	  
the	   advanced	   stages	   of	   the	   disease,	   and	   their	   presence	   at	   the	   diagnosis	  
characterize	   a	   worse	   prognosis.	   MPM	   might	   spread	   to	   the	   abdomen	  
through	   the	   diaphragm,	   and	   in	   the	   30%	   of	   the	   patients	   the	   main	  
complication	  is	  bowel	  occlusion,	  while	  rarely	  the	  invasion	  of	  liver	  or	  other	  
organs	   is	   observed.	   About	   10%	   of	   the	   patients	   might	   die	   because	   of	  
myocardial	  or	  pericardial	  involvement.	  Distant	  metastases	  are	  uncommon,	  
and	   generally	  more	   frequent	   in	   the	   sarcomatoid	   subtype.	  MPM	   patients	  
usually	  die	  because	  of	  respiratory	  insufficiency	  o	  pneumonitis.	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The	  2004	  WHO	  (World	  Health	  Organization)	  classification	  of	  pleural	  tumors	  
have	  described	  three	  main	  MPM	  histologic	  subtypes:	  epithelioid	  (50-­‐67%),	  
sarcomatoid	  (7-­‐21%)	  and	  biphasic	  (24-­‐35%),	  each	  of	  them	  characterized	  by	  
different	  biological	  and	  clinical	  behaviour[24]	  [25].	  
Epithelioid	   mesothelioma,	   associated	   to	   a	   more	   favourable	   prognosis,	   is	  
characterized	   by	   cells	   distributed	   into	   three	   different	   patterns:	   solid,	  
glandular	  and	  tubulo-­‐papillar.	  
Sarcomatoid	   mesothelioma	   is	   biologically	   more	   aggressive,	   and	  
characterized	   by	   fusiform	   cells	   organized	   in	   layers	   or	   folders	   (typical)	   or	  
sometimes	   in	   a	   disorganized	   pattern	   associated	   with	   abundant	   stroma	  
(desmoplastic).	  	  
The	   immunohistochemistry	   diagnosis	   uses	   panels	   which	   combine	  
mesothelioma	  and	  cancer	  associated	  markers.	  The	  immunohistochemistry	  
usually	   consists	   on	   subsequent	   steps,	   using	   first	   two	   markers	   for	   MPM	  
(calretinin,	   podoplanin)	   and	   two	   for	   another	   cancer	   (usually	   lung	  
adenocarcinoma:	  TTF1,	  CEA).	  
Surgical	   resection	   of	   MPM	   is	   feasible	   in	   a	   small	   percentage	   of	   patients,	  
although	   selection	   criteria	   have	   not	   been	   identified	   yet	   in	   prospective	  
series	  [26].	  
Pleurectomy/Decortication	   (P/D)	   leads	   to	   a	   significant	   but	   incomplete	  
resection	  of	  the	  tumoral	  pleura,	   leaving	  the	   involved	  lung	  free	  to	  expand.	  
This	   procedure	   has	   not	   a	   curative	   intent,	   but	   it	   may	   be	   considered	   in	  
symptomatic	   patients	   in	   order	   to	   control	   pain	   and	   restrictive	   deficit[27].	  
Radical	   surgery	   consists	   on	   the	   complete	   resection	   of	   cancer	   tissue	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macroscopically	   visible,	   and	   it	   may	   be	   achieved	   with	   extrapleural	  
pneumonectomy	   (EPP):	   en-­‐bloc	   resection	   of	   pleura,	   lung,	   pericardium,	  
diapraghm,	  lymphnodes.	  In	  the	  attempt	  of	  reducing	  the	  incidence	  of	  local	  
recurrences	  after	  extrapleural	  pneumonectomy,	  a	  multimodality	  approach	  
with	   surgery	   followed	  by	  postoperative	   radiotherapy	  was	  explored	   in	   the	  
past	   years.	   Extrapleural	   pneumonectomy	   allows	   higher	   doses	   of	  
radiotherapy	  to	  the	  whole	  hemithorax	  by	  avoiding	  pulmonary	  toxicity	  and	  
the	   result	   of	   this	   approach	   is	   a	   significant	   reduction	   of	   loco-­‐regional	  
relapses.	  
The	   issue	  of	  extrathoracic	  metastasis	   represents	  a	  major	   challenge	   in	   the	  
management	   of	   the	   disease	   because	   of	   the	   impact	   on	   overall	   survival.	  
Once	   a	   chemotherapy	   regimen	   shows	   activity	   in	   advanced	   malignant	  
pleural	   mesothelioma,	   a	   subsequent	   step	   was	   the	   addition	   of	   such	  
treatment	  to	  surgery	  and	  radiotherapy	  to	  improve	  the	  
systemic	   control	   of	   the	   disease.	   The	   success	  with	   surgical	   resection	   after	  
neoadjuvant	   chemotherapy	   in	   stage	   IIIA	   non-­‐small	   cell	   lung	   cancer	   has	  
been	   the	   impetus	   for	   several	   groups	   to	   apply	   this	   strategy	   in	   malignant	  
mesothelioma	  aiming	  at	  reducing	  the	  incidence	  of	  distant	  relapse.	  As	  well	  
as	   in	   non-­‐small	   cell	   lung	   cancer,	   neoadjuvant	   chemotherapy	   could	  
maximize	   cytoreduction	   and	   increase	   the	   proportion	   of	   patients	   able	   to	  
complete	   the	   following	   treatments.	   Furthermore,	   the	   difficult	  
administration	   of	   both	   postoperative	   chemotherapy	   and	   radiotherapy	   in	  
most	   patients	   induced	  many	   groups	   to	   introduce	   a	   trimodality	   approach	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based	   on	   preoperative	   chemotherapy,	   surgery	   and	   postoperative	  
radiotherapy	  in	  the	  attempt	  of	  improving	  compliance[28].	  	  
Recently	   the	   MARS	   (Mesothelioma	   And	   Radical	   Surgery)	   study,	   the	   first	  
study	   which	   randomized	   between	   extrapleural	   pneumonectomy	   and	   no	  
extrapleural	   pneumonectomy,	   showed	   no	   survival	   advantage	   and	   worse	  
quality	   of	   life	   in	   those	   patients	   who	   underwent	   surgery.	   The	   trial	   had	  
several	   limitations;	   patients	   were	   treated	   with	   different	   chemotherapy	  
regimens,	   and	   in	   a	   relevant	   percentage	   of	   cases	   a	   sub-­‐optimal	  
chemotherapy	   was	   delivered.	   The	   heterogeneity	   of	   delivered	  
chemotherapy	   could	   have	   unbalanced	   the	   two	   study	   arms.	   The	   study	  
population	  was	   small	   but	   the	   conclusion	  of	   the	   trial	   raised	   the	   issue	  of	   a	  
less	   invasive	   approach	   as	   suitable	   treatment	   of	   malignant	   pleural	  
mesothelioma[29].	  
Chemotherapy	   is	   still	   the	   treatment	   option	   for	   the	   majority	   of	   MPM	  
patients	  not	  suitable	  for	  surgical	  resection.	  Currently,	  the	  gold	  standard	  in	  
the	  systemic	  treatment	  of	  MPM	  patients	  is	  a	  chemotherapy	  regimen	  based	  
on	  a	  platinum-­‐base	  doublet	  plus	  an	  antifolate	  agents	  such	  as	  pemetrexed	  
or	   raltitrexed,	   which	   showed	   survival	   and	   response	   improvement	  
compared	  with	  platinum	  single	  agent.	  These	  combinations	  showed	  median	  
overall	   and	   progression	   free	   survival	   of	   approximately	   12	   and	   6	   months	  
respectively,	  and	  a	  response	  rate	  of	  20-­‐40%[1,	  2].	  Carboplatin	  is	  considered	  
a	   valid	   option	   in	   the	   systemic	   treatment	   of	   advanced	   pleural	  
mesothelioma,	  with	  better	  toxicity	  profile	  compared	  to	  cisplatin	  [30-­‐32].	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After	  first-­‐line	  treatment	  failure	  and	  disease	  progression	  or	  relapse,	  there	  
is	  not	  a	  systemic	  regimen	  showing	  significant	  improvement	  in	  survival	  and	  
quality	  of	  life,	  and	  few	  data	  of	  second	  line	  treatment	  are	  reported	  in	  small	  
phase	   II	   studies	   or	   retrospective	   case	   series,	   thus	   raising	   some	   doubts	  
about	   which	   might	   be	   the	   right	   drug	   for	   the	   right	   patient	   in	   previously	  
treated	  subjects.	  
The	   improvement	   of	   knowledge	   about	   biological	   behaviour,	   molecular	  
pathways	   and	   genetic	   alterations	   of	   MPM,	   lead	   to	   the	   preclinical	   and	  
clinical	  investigation	  of	  new	  targeted	  agents	  in	  this	  setting.	  VEGF	  and	  other	  
antiangiogenetic	   drugs,	   agents	   against	   other	   growth	   factors,	   HDAC	   and	  
proteasome	  inhibitors,	  PI3K/mTOR	  inhibitors	  have	  been	  explored,	  although	  
these	   drugs	   have	   not	   found	   a	   specific	   role	   in	   the	   therapeutic	  
armamentarium	  of	  this	  disease[33].	  
2.2 Extrinsec	  and	  intrinsec	  apoptosis:	  TRAIL	  and	  p53-­‐MDM2	  pathway	  
2.2.1	   Tumor	  necrosis	   factor-­‐related	  apoptosis-­‐inducing	   ligand	   (TRAIL)	   and	  
MPM.	  
Tumor	  necrosis	  factor-­‐related	  apoptosis-­‐inducing	  ligand	  (TRAIL)	  belongs	  to	  
the	   tumor	   necrosis	   factor	   (TNF)	   family	   of	   death	   ligands	   inducing	   the	  
extrinsic	  apoptotic	  pathway.	  Two	  surface	  death	  receptors	  (TRAIL-­‐R1	  or	  DR4	  
and	   TRAIL-­‐R2	   or	   DR5),	   two	   decoy	   non-­‐functional	   receptors	   (TRAIL-­‐R3	   or	  
DcR1	   and	   TRAIL-­‐R4	   or	   DcR2)	   and	   the	   soluble	   decoy	   receptor	  
osteoprotegerin	   were	   described	   [34-­‐39].	   After	   the	   binding	   of	   TRAIL	   to	  
DR4/5	   and	   the	   oligomerization	   of	   death	   receptors,	   the	   death-­‐inducing	  
	   21	  
signalling	  complex	  (DISC)	  is	  formed,	  which	  includes	  also	  the	  Fas-­‐associated	  
death	  domain	  (FADD).	  
FADD	  recruits	  and	  initiates	  procaspase	  8	  to	  active	  caspase	  8	  which	  in	  turn	  
cleaves	  and	  activates	  the	  effector	  caspases	  3,	  6	  and	  7.	  	  
TRAIL	   has	   been	   identified	   as	   a	   promising	   anticancer	   agent	   thanks	   to	   its	  
property	   of	   killing	   cancer	   cells	   while	   sparing	   normal	   cells	   [40,	   41],	   even	  
though	   both	   sensitivity	   and	   resistance	  mechanisms	   to	   TRAIL-­‐induced	   cell	  
death	  are	  not	  completely	  clarified	  [42].	  	  
TRAIL-­‐induced	   death	   program	   is	   successfully	   executed	   in	   “type	   I”	   cells,	  
while	  “type	  II”	  cells	  need	  the	  activation	  of	  the	  intrinsic	  apoptotic	  pathway	  
[43],	   through	  activation	  of	  the	  BH3-­‐only	  protein,	  Bid,	  which	  moves	  to	  the	  
mithocondria	  where	   contributes	   to	   Bax	   and	   Bak	   activation.	   The	   resulting	  
mithocondrial	   pore	   formation	   leads	   to	   cytochrome	   c	   release	   into	   the	  
cytosol	  with	  the	  final	  caspase	  9	  activation.	  Moreover,	  “type	  II”	  cancer	  cells	  
seem	   sensitive	   to	   the	   synergistic	   effect	   of	   TRAIL,	   acting	   on	   the	   extrinsic	  
pathway,	   and	  DNA	  damaging	   agents,	   targeting	   the	   intrinsic	   pathway;	   the	  
mechanism	  of	  this	  synergy	  has	  been	  proposed	  to	  be	  via	  the	  upregulation	  of	  
the	  TRAIL	  receptor	  DR5	  [44-­‐46].	  
Cancer	  cells	  are	  frequently	  resistant	  to	  TRAIL-­‐dependent	  apoptosis	  through	  
different	  mechanisms:	  mutations	  and	  disfunction	  of	  DR4	  and	  DR5;	  defects	  
of	   Fas-­‐associated	  death	  domain	   (FADD)	  and	  caspase	  8;	  overexpression	  of	  
cellular	   FADD-­‐like	   interleukin-­‐1b-­‐converting	   enzyme	   inhibitory	   protein	  
(cFLIP);	   overexpression	   of	   the	   antiapoptotic	   proteins	   Bcl-­‐2,	   Bcl-­‐Xl,	   IAPs	  
(Inhibitor	   of	   Apoptosis	   Proteins);	   loss	   of	   proapoptotic	   proteins	   Bax,	   Bak;	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decreased	   release	   of	   second	   mithocondria-­‐derived	   activator	   of	   caspases	  
(Smac-­‐Diablo);	   activation	   of	  mitogen-­‐activated	   protein	   kinases	   (MAPK)	   or	  
NFKB	  [42].	  	  
Monoclonal	   agonist	   antibodies	   directed	   against	   the	   DR4	   and	   DR5	  
(Mapatumumab,	   Lexatumumab,	   Apomab,	   AMG655,	   LBY135)	   and	  
recombinant	  human	  Apo2L/TRAIL	  (rhApo2L/TRAIL,	  Dulanermin)	  have	  been	  
studied	   at	   a	   preclinical	   and	   clinical	   level	   both	   as	   single	   agents	   and	   in	  
combination	  with	  chemotherapy	  [47-­‐52].	  	  
Recombinant	   human	   (rh)	   Apo2L/TRAIL	   (Dulanermin),	   a	   receptor	   agonist	  
which	  binds	  both	  DR4	  and	  DR5[53,	  54],	  showed	  antitumor	  activity	   in	  vitro	  
and	  in	  vivo	  tumor	  models	  of	  different	  cancer	  types	  both	  as	  single	  agent	  and	  
in	  combination	  with	  chemotherapy	  without	  any	  toxicity	  in	  normal	  cells	  [55-­‐
57],	  and	  was	  the	  first	  TRAIL	  agonist	  investigated	  in	  human	  clinical	  trials	  [51,	  
52,	  58].	  
Conflicting	   evidences	   about	   MPM	   resistance	   rather	   than	   sensitivity	   to	  
TRAIL-­‐induced	  apoptosis	  were	  previously	  reported	  [49,	  59].	  A	  Swiss	  group	  
showed	   apoptotic	   effects	   of	   TRAIL	   or	   the	   monoclonal	   antibodies	  
Mapatumumab	   and	   Lexatumumab	   directed	   against	   DR4	   and	   DR5	   on	   13	  
MPM	   cell	   lines;	   moreover,	  Mapatumumab	   (anti	   DR4)	   and	   Lexatumumab	  
(anti	   DR5)	   sensitized	  MPM	   cell	   lines	   to	   the	   cytotoxic	   effects	   of	   Cisplatin,	  
and	   cell	   death	   occurred	   through	   a	   synergistic	   cooperation	   of	   the	   two	  
agents	   (Mapatumumab	  or	  Lexatumumab	  plus	  Cisplatin)	  probably	   through	  
Reactive	  Oxygen	  Species	  (ROS)	  induction[49].	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Increased	   apoptotic	   levels	   were	   demonstrated	   in	   four	   cell	   lines	   treated	  
with	   the	   association	   of	   TRAIL	   and	   chemotherapy	   (Cisplatin,	   Doxorubicin,	  
Gemcitabine	   or	   Etoposide),	   probably	   through	   p53-­‐independent	   apoptotic	  
pathway;	   no	   DR5	   increase	   was	   observed	   at	   the	   basis	   of	   this	  
sensitization[60].	  	  
Other	   studies	   showed	   a	   p53-­‐dependent	   induction	   of	   DR4	   and	   DR5	  
expression	   by	  Alpha-­‐tocopheryl	   succinate,	   resulting	   in	   TRAIL	   sensitization	  
[61].	  While	  TRAIL-­‐dependent	  apoptosis	  is	  thought	  to	  be	  p53-­‐independent,	  
p53	  wild	  type	  cancer	  cells	  can	  be	  sensitized	  to	  TRAIL	  through	  p53	  activation	  
[62].	   In	  contrast	   to	  most	  solid	   tumors,	  MPM	  cells	   frequently	  express	  wild	  
type	  p53	  [63],	  thus	  p53	  reactivation	  through	  different	  strategies	  might	  be	  
considered	   as	   an	   effective	   strategy	   to	   sensitize	   MPM	   cells	   to	   TRAIL-­‐
dependent	  apoptosis.	  
2.2.2	  p53-­‐MDM2	  pathway	  and	  MPM.	  
The	   tumor	   suppressor	  p53	  acts	   as	   a	   transcription	   factor	   regulating	   genes	  
involved	   in	   DNA	   repair,	   metabolism,	   cell	   cycle	   arrest,	   apoptosis	   and	  
senescence.	   It	   was	   defined	   as	   the	   ‘guardian	   of	   genome’	   because	   of	   its	  
ability	   of	   preserving	   the	   genomic	   integrity	   of	   the	   cell	   under	   stressed	  
conditions;	   p53	   disruption,	   subsequently,	   leads	   to	   increased	   cancer	   risk	  
and	  to	  a	  worse	  cancer	  prognosis	  and	  treatment	  response.	  
Under	   unstressed	   conditions,	   p53	   levels	   are	   kept	   low	   by	   a	   feedback	  
interaction	   with	   the	   RING	   domain	   proteins	   murine	   double	   minute	   2	  
(MDM2)	   and	  MDM4	   (also	   known	   as	  MdmX).	  MDM2	   is	   a	   target	   of	   p53’s	  
transcriptional	   activity,	   with	   E3	   ubiquitin	   ligase	   activity:	   once	   activated,	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MDM2	  binds	  p53	  to	  the	  amino-­‐terminus,	  targeting	  it	  for	  ubiquitylation	  and	  
subsequent	   proteasomal	   degradation	   which	   represents	   its	   main,	   and	  
probably	   first	   known,	   function[64].	   MDM2	   inhibits	   p53	   through	  multiple	  
other	  inhibitory	  mechanisms,	  such	  as	  the	  prevention	  of	  the	  transcriptional	  
coactivator	   recruitment,	   the	   inhibition	   of	   p53-­‐DNA	   interaction	   and	   p53	  
indirect	  translation[65].	  
Under	  stressed	  condition	  -­‐	  such	  as	  DNA	  damage-­‐	  induced	  p53	  decides	  cell	  
fate	  outcomes	  among	  apoptosis,	  cell	  cycle	  arrest	  and	  senescence	  through	  
specific	   gene	   transcription;	   p53’s	   promoter	   selectivity,	   the	   levels	   of	   the	  
protein	   itself,	   antiapoptotic	  proteins	   levels,	   specific	   cofactors	   recruitment	  
for	   downstream	   genes	   transcription,	   post-­‐translational	   p53	  modifications	  
seem	   to	   condition	   cell	   death	   rather	   than	   cell	   cycle	   arrest	   or	  
senescence[66].	  	  
p53	   is	  mutated	   in	   about	   50%	  of	   the	  human	   cancers[67],	  while	   in	   tumors	  
with	   wild-­‐type	   p53	   gene,	   the	   protein	   function	   may	   be	   lost	   because	   of	  
overexpression	  of	  p53	   regulatory	  proteins	   such	  as	  MDM2	  and	  MDM4,	  or	  
because	  of	  CDKN2A	  –encoding	  for	  ARF	  which	  binds	  to	  and	  rapidly	  degrades	  
MDM2-­‐	   deletions.	   MDM2	   and	   MDM4	   protein	   overexpression	   with	   or	  
without	  increased	  gene	  copy	  number	  occurs	  in	  several	  cancer	  types,	  more	  
frequently	  in	  those	  tumors	  with	  a	  wild-­‐type	  p53[68].	  	  
MDM2	  and	  MDM4	  amplification	  have	  been	  shown	  in	  about	  30%	  and	  17%	  
of	   soft	   tissue	   sarcomas	   (STS)	   respectively,	   while	   p53	   mutations	   and	  
CDKN2A	   deletions	   were	   described	   in	   about	   20	   and	   15%	   of	   the	   cases,	  
respectively[69-­‐72].	   A	   recent	   p53-­‐pathway	   mapping	   in	   different	   STS	  
	   25	  
histologic	   subtypes,	   confirmed	   frequent	   p53	   mutations	   in	  
leiomyosarcomas,	   osteosarcomas	   and	   pleomorphic	   sarcomas,	   while	  
frequent	   MDM2	   amplifications	   in	   well	   differentiated	   liposarcomas	   and	  
MDM4	  in	  Ewing’s	  sarcoma/PNETs;	  MDM2	  and	  MDM4	  coamplification	  was	  
a	  common	  event	   in	  synovial	   sarcomas,	  Ewing’s/PNET	  and	  osteosarcomas.	  
Moreover,	  p53	  mutations	  and	  MDM2	  amplifications	  appeared	  as	  mutually	  
exclusive	   events,	  which	   acquire	   particular	   relevance	   in	   patients	   selection	  
for	  p53-­‐reactivating	  treatments[73].	  However,	  gene	  amplification	  is	  not	  the	  
only	  mechanism	  sustaining	  MDM2	  overexpression[74-­‐76].	  
Transcriptional	   and	  post-­‐transcriptional	  mechanisms	  have	  been	  proposed	  
at	   the	   basis	   of	   MDM2	   and	   MDM4	   overexpression,	   thanks	   to	   the	   dense	  
interaction	   network	   of	   these	   proteins[77].	   Among	   post-­‐transcriptional	  
modifications,	  post-­‐translational	  modifications	  acquire	  particular	  relevance	  
in	  MDM2	   regulation,	   and	   phosphorylation	   is	   one	   of	   the	  most	   commonly	  
implied	  in	  different	  conditions.	  This	  post-­‐translational	  modification	  leads	  to	  
p53	   ubiquitination	   and	   degradation	   and	   to	   the	  MDM2-­‐p19ARF	   interaction	  
prevention,	  finally	  to	  MDM2	  nucleus-­‐cytoplasm	  shuttling.	  
Heterogeneous	  data	  across	  tumor	  types	  have	  been	  reported	  about	  MDM2	  
overexpression	  with	  or	  without	  gene	  amplification,	   and	  about	  a	  possibile	  
prognostic	  role	  of	  such	  marker[78]	  but	  its	  protoncogenic	  activity,	  both	  p53	  
dependent	  and	   independent,	   suggests	   this	  may	  be	  a	  promising	   target	   for	  
treatment.	  
The	  majority	   of	  MPM	   tumor	   specimens	   have	   p53	   wild	   type	   but	   present	  
deletion	  of	  the	  locus	  INK4A/ARF	  (70-­‐80%)	  that	  contains	  the	  genes	  p14/ARF	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and	  p16/INK4A[79]	  p14/ARF	   is	  crucial	   in	  controlling	  cell	  proliferation.	   It	   is	  
activated	  by	  oncogenic	  triggers	  and	  acts	  by	  binding	  to	  MDM2,	  sequestering	  
it	  in	  the	  nucleolus	  and,	  so,	  inhibiting	  its	  functions	  as	  p53	  negative	  regulator	  
[80].	  p14/ARF	  deletion	  has	  a	  significant	  role	   in	  driving	  MPM	  pathogenesis	  
in	   vivo	   [81]	   Despite	   this,	   several	   evidences	   demonstrate	   that	   the	   p53	  
pathway,	   downstream	   p14/ARF,	   is	   functional	   and	   that	   p53	   activation	   is	  
able	   to	   induce	   apoptosis	   in	   absence	   of	   p14/ARF[82].	   The	   introduction	   of	  
p14	  gene	  in	  INK4A/ARF-­‐deficient	  MPM	  cell	  lines	  induced	  activation	  of	  p53	  
and	  subsequent	  cell	  cycle	  arrest	  and	  apoptosis[83].	  	  
Investigations	   on	   the	   MDM2-­‐p53	   interaction	   provided	   a	   basis	   for	   the	  
design	   of	   novel	   small	   molecules	   targeting	   the	   MDM2	   activity,	   possibly	  
reactivating	   the	   wild-­‐type	   p53	   function.	   Previous	   evidence	   reported	   the	  
discovery	  of	  a	  series	  of	  4,5-­‐dihydroimidazolines	  called	  Nutlins.	  Compound	  
1,	   also	   known	   as	   Nutlin-­‐3a,	   has	   become	   a	   tool	   of	   choice	   to	   study	   p53	  
biology	  and	  therapeutic	  applications.	  Although	  these	  early	  lead	  compounds	  
have	  shown	  good	  cellular	  activity	  and	  provided	   the	  mechanistic	  proof-­‐of-­‐
concept	   for	   inhibiting	   p53-­‐MDM2	   interaction	   for	   cancer	   therapy,	   their	  
pharmacological	  properties	  were	  suboptimal	  for	  clinical	  development[84].	  
Optimization	  efforts	  led	  to	  the	  discovery	  of	  a	  new	  member	  of	  the	  Nutlin3	  
family	  of	  MDM2	   inhibitors,	  RG7112	  which	   is	   currently	  being	  evaluated	   in	  
human	  clinical	  trials.	  
RG7112	   is	   the	   first	   clinical	   small-­‐molecule	   MDM2	   inhibitor	   designed	   to	  
occupy	   the	  p53-­‐binding	  pocket	  of	  MDM2.	   In	  cancer	  cells	  expressing	  wild-­‐
type	  p53,	  RG7112	  stabilizes	  p53	  and	  activates	  the	  p53	  pathway,	  leading	  to	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cell	   cycle	   arrest,	   apoptosis,	   and	   inhibition	   or	   regression	   of	   human	   tumor	  
xenografts[85].	  
2.3 Neoangiogenesis	  and	  MPM	  
VEGF	   (Vascular	   Endothelial	   Growth	   Factor)	   is	   an	   autocrine	   growth	   factor	  
released	  by	  MPM	  cells	  which	  binds	  endothelial	  cell	  receptors	  and	  induces	  
new	  blood	  vessels	  formation.	  VEGF	  levels	  are	  higher	  in	  MPM	  patients	  than	  
in	   healthy	   individuals	   or	   patients	   with	   non	   neoplastic	   pleural-­‐pulmonary	  
disease	  or	  patients	  with	  other	  solid	  malignancies;	  high	  levels	  of	  this	  growth	  
factor	   are	   associated	   to	   microvessels	   density	   and	   poor	   prognosis.	   These	  
data	  suggest	  that	  VEGF	  may	  be	  a	  proper	  target	  for	  MPM	  treatment[33,	  86,	  
87].	  Treatment	  of	  MPM	  cell	  lines	  with	  rhVEGF	  (recombinant	  human	  VEGF)	  
induces	   MPM	   proliferation	   and	   this	   effect	   is	   abrogated	   by	   using	   VEGF	  
blocking	   antibodies[88,	   89]	   demonstrating	   that	   VEGF	   has	   a	   role	   both	   in	  
angiogenesis	  and	  cell	  proliferation.	  These	   results	  offer	  a	   rationale	   for	   the	  
use	   of	   antiangiogenic	   therapies	   in	   MPM	   patients.	   Nevertheless,	  
antiangiogenic	   therapy	   in	   MPM	   did	   not	   achieve	   the	   expected	   results.	  
Bevacizumab,	  a	  recombinant	  humanized	  monoclonal	  antibody	  that	  inhibits	  
the	   binding	   of	   VEGF	   to	   its	   receptors,	  was	   clinically	   investigated	   in	  MPM.	  
Simultaneous	   administration	   of	   Bevacizumab	   plus	   cisplatin/gemcitabine,	  
Cisplatin/Pemetrexed	   or	   Carboplatin/Pemetrexed	   did	   not	   improve	   the	  
overall	   survival	   of	  MPM	  patients[90-­‐93].	   These	   results	   demonstrate	   that,	  
although	  anti-­‐VEGF	   target	   therapy	  may	  be	  a	  promising	   strategy	   for	  MPM	  
treatment,	  it	  is	  important	  to	  individuate	  a	  new	  molecular	  marker	  to	  predict	  
the	  efficacy	  of	  anti-­‐angiogenic	  therapies.	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Recently,	  many	  researchers	  have	   investigated	  a	  possible	  role	  of	  MDM2	  in	  
promoting	   tumor	   neoangiogenesis	   through	   the	   regulation	   of	   VEGF	  
expression	  and	  probably	  other	  factors	  involved	  in	  this	  biological	  process.	  	  
Physiologically,	  MDM2	   seems	   to	   be	   entailed	   in	   exercise-­‐induced	  muscles	  
vascularization[94].	   In	   pathological	   condition,	   hypoxia	   might	   induce	  
expression	  of	  MDM2	  which	  in	  turns	  binds	  and	  stabilizes	  Hypoxia-­‐Inducible	  
Factor	   (HIF)-­‐1alpha,	   a	   transcription	   factor	   responsible	   for	   VEGF	  
transcription[95].	   In	   agreements	   with	   this	   observation,	   LaRusch	   and	   co-­‐
workers	  demonstrated	  that	  the	  inhibition	  of	  MDM2-­‐HIF-­‐1alpha	  interaction	  
by	  Nutlin-­‐3a	  reduces	  VEGF	  mRNA	  expression[96].	  
An	  alternative	  mechanism	  by	  which	  MDM2	  regulates	  VEGF	  it	  was	  proposed	  
by	  Zhou	  and	  colleagues.	  They	  demonstrated	  that	  MDM2	  binds	  the	  3’UTR	  of	  
VEGF	  and	  stabilizes	  VEGF	  mRNA.	  In	  their	  work	  they	  suggested	  that	  hypoxia	  
provokes	  MDM2	   translocation	   from	   the	   nucleus	   to	   the	   cytoplasm	  where	  
MDM2	   interacts	   with	   VEGF	   mRNA	   inducing	   high	   levels	   of	   VEGF	   in	   the	  
cells[97].	  
The	   same	   mechanisms	   seems	   to	   be	   at	   the	   basis	   of	   VEGF	   expression	  
regulation	   in	   breast	   cancer	   cell	   lines,	   independenty	   from	   the	   p53	   status.	  
Moreover,	   the	   administration	   of	  MDM2	   inhibitors	   in	   nude	  mice	   injected	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3. Aims	  
The	   general	   purpose	   of	   the	   present	   study	   comes	   from	   unanswered	  
scientific	   questions	   and	   unmet	   medical	   needs	   in	   the	   knowledge	   and	  
medical	  management	  of	  Malignant	  Pleural	  Mesothelioma.	  	  
Considering	   the	   poor	   prognosis	   of	   affected	  patients,	   the	   lack	   of	   effective	  
treatment	  options,	  with	  particular	  reference	  to	  biologic	  drugs,	  and	  absence	  
of	   predictive	   markers	   for	   targeted	   treatment,	   the	   first	   purpose	   was	   to	  
investigate	   new	   treatment	   options	   through	   preclinical	   evaluation	   of	  
extrinsic	   apoptosis	   triggers	   (recombinant	   human	   Apo2L/TRAIL)	   in	  
combination	   with	   intrinsic	   apoptosis	   inducers	   acting	   through	   the	  
reactivation	  of	  p53.	  	  
Moreover,	   the	   study	   aims	   at	   investigating	   new	   targets	   for	   treatment	   in	  
MPM	   cell	   lines	   and	   tumor	   samples,	   investigating	   possible	   different	  
expression	  levels	  of	  such	  targets	  in	  the	  different	  histologic	  subtypes.	  	  
Finally,	  considering	  the	  lack	  of	  knowledge	  about	  the	  genetic	  and	  molecular	  
mechanisms	  at	  the	  basis	  of	  different	  biological	  behaviour	  of	  the	  two	  main	  
mesothelioma	   histologic	   subtypes	   (epithelioid	   and	   sarcomatoid/biphasic)	  
the	   project	   tried	   to	   put	   on	   evidence	   some	   difference	   between	   different	  
histologic	   subtypes	   of	   mesothelioma	   samples	   in	   terms	   of	   pathological	  
features.	   We	   achieved	   the	   project’s	   aims	   according	   to	   the	   following	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3.1	   Preclinical	   evaluation	   of	   the	   anticancer	   activity	   of	   the	   extrinsic	  
apoptosis	   activator	   (rhApo2L/TRAIL)	   in	   combination	   with	   intrinsic	  
apoptosis	  triggers	  acting	  through	  p53	  activation	  	  
Even	   though	  TRAIL-­‐induced	  apoptosis	   is	   believed	   to	  be	  p53-­‐independent,	  
several	   and	   complex	   interactions	   between	   the	   two	   pathways	   were	  
reported	   suggesting	   that	   targeting	   p53	  might	   be	   a	   promising	   strategy	   to	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sensitize	   tumors	   with	   wild-­‐type	   p53	   (e.g.	  MPM)	   to	   TRAIL-­‐dependent	   cell	  
death	  [15,	  62].	  	  
The	   first	   aim	   of	   this	   study	   is	   to	   investigate	   the	   anticancer	   effects	   of	  
rhApo2L/TRAIL	   (Amgen/Genentech)	   in	   combination	  with	   p53	   reactivating	  
agents	   such	   as	   chemotherapy	   and	   p53-­‐MDM2	   inhibitors,	   employing	  
epithelioid	   and	   sarcomatoid	   MPM	   cell	   lines	   and	   an	   in	   vivo	   preclinical	  
model.	  
3.1.1.	   First,	  we	   investigated	   the	  anticancer	  activity	  of	   rhApo2L/TRAIL	  plus	  
the	   current	   gold	   standard	   chemotherapy	   regimen,	   a	   platinum-­‐based	  
doublet	  associated	  with	  the	  antifolate	  agent	  pemetrexed.	  We	  furthermore	  
investigated	   if	   the	   improved	   cytotoxicity	   after	   the	   combination	   of	  
rhApo2L/TRAIL	  plus	  chemotherapy	  was	  actually	  p53-­‐dependent.	  
3.1.2.	   We	   also	   explored	   the	   association	   of	   rhApo2L/TRAIL	   plus	   a	   new	  
member	  of	   the	  Nutlin3	   family	  of	  MDM2	   inhibitors,	  RG7112	   (Hoffmann-­‐La	  
Roche	  Inc).	  
3.2	   Translational	   study	   of	   the	   identification	   of	   pathological	   and	   molecular	  
differences	  in	  chemonaive	  tumor	  samples	  from	  different	  MPM	  histologic	  
subtypes	  (epithelioid	  versus	  non-­‐epithelioid)	  
Druggable	   molecular	   difference	   between	   epithelioid	   and	   sarcomatoid	  
MPM	   has	   not	   been	   identified	   so	   far.	   Preliminary	   results	   suggest	   that	  
MDM2	   might	   promote	   tumor	   growth	   through	   apoptosis	   inhibition	   and	  
neoangiogenesis	   (VEGF	   and	   HIF1alpha)	   induction.	   According	   to	   our	  
preliminary	  data,	  this	  protein	  might	  be	  expressed	  at	  different	  levels	  in	  the	  
two	  MPM	  histologic	  subtypes.	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Through	  the	  analysis	  of	  chemonaive	  patients	  samples	  the	  aim	  of	  this	  study	  
is	  to	  describe	  the	  different	  MPM	  histologic	  subtypes	  in	  terms	  of:	  
-­‐	   possible	   molecular	   targets	   for	   treatment–	  MDM2,	   VEGF,	   HIF1alpha-­‐	   at	  
mRNA	   and	   protein	   level;	   the	   correlation	   of	   MDM2	   and	   neoangiogenesis	  
markers	  expression	  level	  have	  been	  explored.	  
-­‐	   pathological	   features	   –necrosis,	   inflammation	   and	   proliferation	   index-­‐	  
and	  their	  correlation	  with	  MDM2	  expression	  levels	  
-­‐	   as	   exploratory	   endpoints	   we	   aim	   at	   describing	   a	   possible	   prognostic	  
and/or	  predictive	  role	  of	  MDM2	  and	  other	  markers/histological	  features.	  
4. Methods	  
4.1	  Preclinical	  evaluation	  of	  the	  anticancer	  activity	  of	  the	  extrinsic	  apoptosis	  
activator	  (rhApo2L/TRAIL)	  in	  combination	  with	  intrinsic	  apoptosis	  triggers	  
acting	  through	  p53	  activation	  (chemotherapy;	  RG7112)	  
4.1.1.Cell	  lines	  and	  primary	  cultures	  
Peripheral	  Blood	  Mononuclear	  Cells	  (PBMC)	  were	  isolated	  from	  peripheral	  
blood	   of	   healthy	   donors	   using	   Ficoll-­‐Paque	   PLUS	   (GE	   HEALTHCARE,	   Little	  
Chalfont,	  Buckinghamshire,	  U.K.)	  according	  to	  the	  manufacturer’s	  protocol.	  	  
We	  employed	  three	  cell	   lines	  of	  epithelioid	  derivation	  (ZL55,	  H28,	  M14K),	  
three	   biphasic	   cell	   lines	   (ZL5,	   SPC111,	  MSTO-­‐211H)	   and	   the	   sarcomatoid	  
cell	   line	  ZL34.	  PBMC	  and	  MPM	  cell	   lines	  were	  maintained	   in	  Roswell	  Park	  
Memorial	   Institute	   medium	   (RPMI)	   1640	   (Gibco-­‐Life	   Technologies,	  
Carlsbad,	   CA,	   U.S.);	   Human	   Foreskin	   Fibroblasts	   (HFF)	   were	   grown	   in	  
Modified	   Dulbecco’s	   Eagle	   Medium	   (DMEM)	   (Gibco-­‐Life	   Technologies,	  
Carlsbad,	   CA,	   U.S.);	   both	   mediums	   were	   supplemented	   with	   2	   mM	   L-­‐
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glutamine,	   1	   mM	   sodium	   pyruvate,	   10%	   FBS	   and	   1%	   (w/v)	  
penicillin/streptomycin	   (Invitrogen-­‐Life	   Technologies,	   Carlsbad,	   CA,	   U.S.).	  
All	   cells	  were	  cultured	  at	  37°C	   in	  a	  humidified	  atmosphere	  containing	  5%	  
CO2.	  One	  MPM	  primary	  culture	  (MPM1801)	  of	  sarcomatoid	  mesothelioma	  
was	   established	   from	   fresh	   human	   pleural	   mesothelioma	   surgical	  
specimen.	  Specimens	  have	  been	  obtained	  from	  the	  Thoracic	  Surgical	  Unit	  
(University	   of	   Padua),	   after	   patient’s	   informed	   consent	   signature.	   The	  
project	   was	   submitted	   for	   approval	   to	   the	   Ethical	   Committee	   of	   Istituto	  
Oncologico	  Veneto	  and	  to	  the	  Ethical	  Committee	  for	  animal	  studies	  of	  the	  
University	  of	  Padua.	  
4.1.2	  Annexin	  V	  staining:	  	  
MPM	   cells	   were	   seeded	   into	   12-­‐well	   plates	   in	   1.0	   mL/well	   of	   complete	  
RPMI	   1640	   and	   treated	  with	   Carboplatin/Pemetrexed	   (27uM	   and	   42	   uM	  
respectively)	   for	   48	   hours	   or	   Nutlin3a	   10uM	   for	   24	   hours	   and/or	  
rhApo2L/TRAIL	   (Dulanermin,	   Amgen	   Inc,	   Thousand	   Oaks,	   CA,	   U.S.;	  
Genentech	  Inc,	  South	  San	  Francisco,	  CA,	  U.S.)	  50	  ng/mL	  for	  24	  hours.	  	  
In	  vitro	  chemotherapy	  concentrations	  were	  defined	  according	  to	  the	  dose	  
inducing	  the	  higher	  cell	  death	  in	  MPM	  cell	  lines	  with	  the	  lower	  cell	  death	  in	  
normal	  cells	  (PBMC	  and	  fibroblasts).	  	  
Thus,	   we	   choose	   concentration	   of	   Carboplatin	   27uM	   and	   Pemetrexed	  
42uM	   inducing	   10%	   of	   apoptosis	   in	   ZL55;	   the	   same	   concentration	   of	  
Carboplatin	   induced	  about	  5%	  of	  apoptosis	   in	  ZL34,	  while	  Pemetrexed	  as	  
single	  agent	  showed	  no	  apoptosis	  induction	  with	  any	  tested	  concentration	  
(0-­‐100	  uM)	  (data	  not	  shown).	   In	  vitro	  rhApo2L/TRAIL	  concentrations	  were	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defined	   according	   to	   previous	   data	   showing	   that	   these	   are	   able	   to	   reach	  
similar	  blood	  concentrations	  [99].	  
Time	  and	  sequence	  of	  exposure	  to	  chemotherapy	  and	  rhApo2L/TRAIL	  were	  
established	   according	   to	   previous	   data	   with	   other	   TRAIL	   agonists	   and	  
considering	  the	  pharmacokinetic	  of	  the	  drugs	  under	  study	  (shorter	  half-­‐life	  
of	   rhApo2L/TRAIL	   compared	   to	   agonistic	   antibodies	   or	   to	   chemotherapy)	  
[49],[53]	   and	   the	   doubling	   times	   of	   cell	   lines	   (20.89	   hours	   for	   ZL55	   and	  
28.12	  hours	  for	  Zl34,	  data	  not	  shown).	  
The	  Annexin	  V	  assay	  was	  performed	  using	  Annexin-­‐V-­‐Fluos	  and	  PI	  (Roche,	  
Basel,	  Switzerland)	  according	  to	  the	  manufacturers’	  instructions.	  Cells	  were	  
collected,	  centrifuged,	  and	  then	  resuspended	  in	  300	  uL	  of	  Annexin-­‐binding	  
buffer,	   followed	  by	   incubation	  with	  1	  uL	  of	  Annexin	  V-­‐Fluos	  and	  1uL	  of	  PI	  
for	  10	  minutes	  at	  room	  temperature.	  Cells	  positive	  for	  Annexin	  V/PI	  were	  
detected	  by	   flow	  cytometry	  using	  a	  FACSCalibur	  apparatus	  and	  CellQuest	  
software	   (BD	  Biosciences	   San	   Jose,	   CA,	  U.S.).	  Where	   indicated	   cells	  were	  
pre-­‐treated	   with	   the	   ROS	   scavenger	   N-­‐Acetyl-­‐Cysteine	   (NAC	   100	   uM)	  
overnight.	   Specific	   Apoptosis	   was	   calculated	   by	   the	   following	   formula:	  
(percentage	  of	  Annexin	  V	  positive	  cells	   in	   treated	  samples-­‐	  percentage	  of	  
Annexin	   V	   positive	   cells	   in	   untreated	   samples)	   /	   (100-­‐	   percentage	   of	  
Annexin	  V	  positive	  cells	  in	  untreated	  samples)*	  100.	  
Drug	   interactions	  were	   quantified	   by	   determining	   the	   combination	   index	  
(CI)	   using	   the	   CompuSyn	   software	   (ComboSyn,	   Inc.,	   Paramus,	   NJ),	  where	  
CI<	   1,	   CI=1,	   and	   CI	   >	   1	   indicated	   synergistic,	   additive,	   and	   antagonistic	  
effects,	  respectively.	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4.1.3	  Caspases	  Assay:	  
Caspases	   Assay	  was	   performed	   using	   Fluorometric	   Homogenous	   Caspase	  
Assay	   (Roche,	   Basel,	   Switzerland).	   MPM	   cells	   were	   seeded	   into	   96-­‐well	  
plates	   in	   0.1	   mL/well	   of	   complete	   RPMI	   1640,	   treated	   with	  
Carboplatin/Pemetrexed	   (27uM	   and	   42	   uM	   respectively)	   for	   48	   hours	   or	  
Nutlin3a	   10	   uM	   for	   24	   hours	   and/or	   rhApo2L/TRAIL	   (50	   ng/mL)	   for	   24	  
hours,	   and	   then	   incubated	  with	  DEVD-­‐Rhodamine	   110.	  Upon	   cleavage	   of	  
the	   substrate	   by	   activated	   caspases,	   fluorescence	   of	   the	   released	  
Rhodamine	   110	   was	   measured	   using	   Victor	   microplate	   reader	  
(PerkinElmer,	   Waltham,	   Massachusetts,	   U.S.)	   with	   an	   excitation	  
wavelength	   of	   480	   nm	   and	   emission	   wavelength	   of	   520	   nm.	   Specific	  
caspases	   activity	   was	   calculated	   by	   the	   following	   formula:	   (fluorescence	  
intensity	  of	  treated	  samples-­‐	  fluorescence	  intensity	  of	  untreated	  samples)	  /	  
(fluorescence	  intensity	  of	  untreated	  samples).	  
4.1.4	  Western	  blot:	  	  
Tissue	   specimens	  were	   processed	   by	   cryogenic	   grinding	  with	  mortar	   and	  
pestle	  to	  obtain	  a	  fine	  powder.	  The	  tissue	  powders	  and	  the	  cell	  lines	  were	  
lysed	   in	   Mammalian	   Cells	   Disruption	   Buffer	   Paris-­‐Kit	   (Ambion-­‐Life	  
Technologies,	  Carlsbad,	  CA,	  U.S.)	  supplemented	  with	  Phosphatase	  Inhibitor	  
Cocktail	   (Roche,	   Basel,	   Switzerland)	   and	   Complete	   Protease	   Inhibitor	  
Cocktail	  (Roche,	  Basel,	  Switzerland).	  Protein	  concentration	  was	  determined	  
by	   the	   Coomassie	   (Bradford)	   Protein	   Assay	   Kit	   (Thermo	   Scientific,	  
Waltham,	  Massachusetts,	   U.S.)	   using	   bovine	   serum	   albumin	   as	   standard,	  
and	   equal	   amounts	   of	   proteins	   were	   analyzed	   by	   SDS-­‐PAGE	   (12%	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acrylamide/bis-­‐acrylamide).	   Gels	   were	   electroblotted	   onto	  
polyvinylidenedifluoride	   membranes	   (Amersham-­‐GE	   HEALTHCARE,	   Little	  
Chalfont,	   Buckinghamshire,	   U.K.).	   In	   immunoblot	   analysis,	   membranes	  
were	  blocked	   for	   1	  hour	  with	  5%	  non-­‐fat	   dry	  milk	   in	   Tris	   Buffered	   Saline	  
(TBS)	   containing	   0.1%	   Tween-­‐20,	   and	   incubated	   at	   4°C	   over	   night	   with	  
primary	  antibody	  direct	  against	  p53	   (Santa	  Cruz	  Biotechnology),	  p21	   (Cell	  
Signaling	   )	   and	   p53	   (Abcam)	   and	   anti-­‐b-­‐actin	   antibody	   (Sigma)	   used	   as	  
loading	  control,	  followed	  by	  horseradish	  peroxidase-­‐conjugated	  secondary	  
antibodies	   (Santa	   Cruz	   Biotechnology,	   Dallas,	   Texas,	   U.S.).	   Finally,	   the	  
membranes	   were	   incubated	   with	   chemiluminescence	   reagents	  
(Supersignal	  Pico;	  Pierce-­‐Thermo	  Scientific,	  Waltham,	  Massachusetts,	  U.S.)	  
and	  revealed	  using	  Chemidoc	  XRS	  System	  (Biorad,	  Hercules,	  CA,	  U.S.).	  
4.1.5	  Flow	  cytometry	  analysis:	  
Surface	   expression	   of	   TRAIL	   receptors	   was	   evaluated	   by	   indirect	  
immunostaining	   using	   the	   primary	   antibodies	   DR4,	   DR5,	   DcR1	   and	   DcR2	  
(Alexis	   Biochemicals,	   San	   Diego,	   CA,	   U.S.)	   followed	   by	   Alexa	   Fluor	   Goat	  
anti-­‐mouse	   immunoglobulin	   G	   (IgG	   H+L)	   (Life	   Technologies,	   Life	  
Technologies,	   Carlsbad,	  CA,	  U.S.).	  Non-­‐specific	   fluorescence	  was	   assessed	  
using	  normal	  mouse	   IgG	  followed	  by	  secondary	  antibody.	  Flow	  cytometry	  
analysis	   was	   performed	   using	   a	   FACSCalibur	   apparatus	   and	   CellQuest	  
software	  (BD	  Biosciences	  San	  Jose,	  CA,	  U.S.).Relative	  expression	  of	  TRAIL-­‐R	  
was	   calculated	   by	   the	   following	   formula:	   percentage	   of	   positive	   cells	   x	  
mean	  fluorescence	  intensity	  (MFI).	  
4.1.6	  Transfections:	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The	   siRNA	   pool	   (25nM)	   for	   p53	   (RIBOXX-­‐Life	   Science,	   Dresden-­‐Radebeul,	  
Germany)	   and/or	   the	   wild-­‐type	   p53	   expression	   vector	   (200	   ng)	   were	  
transiently	   transfected	   in	   MPM	   cell	   lines	   using	   LIPOFECTAMINE	   2000	  
(Invitrogen-­‐Life	   Technologies,	   Carlsbad,	   CA,	   U.S.),	   according	   to	   the	  
manufacturers’	   instructions.	   The	  expression	   levels	  of	  p53	  were	  evaluated	  
24	  hours	  after	  transfection	  by	  western	  blot	  analysis.	  
4.1.7	  In	  vivo	  experiments:	  
4.1.7.1.	  rhAPO2L/TRAIL	  plus	  chemotherapy	  
In	   vivo	   experiments	   were	   performed	   in	   accordance	   with	   the	   Padua	  
University	  Ethic	  Committee	  for	  Animal	  Testing.	  
60	  SCID	  male	  mice	  at	  the	  6th	  week	  were	  implanted	  subcutaneously	  (sc)	   in	  
the	   right	   flank	   with	   2x106	   ZL55	   (30	   mice)	   or	   ZL34	   cell	   lines	   (30	   mice)	  
suspended	   in	   0.1	   ml	   volume	   of	   RPMI.	   When	   tumor	   volume	   reached	   50	  
mm3,	  mice	  were	  randomized	  in	  four	  groups	  (N=6	  mice/group)	  and	  treated	  
by	  intraperitoneal	  (IP)	   injection:	  not	  treated	  (NT,	  vehicle	  100uL	  on	  day	  1);	  
Carboplatin/Pemetrexed	  (CP,	  75	  mg/Kg	  and	  100	  mg/Kg	  respectively	  on	  day	  
1);	  rhApo2L/TRAIL	  (T,	  60	  mg/Kg	  on	  days	  1,	  2	  and	  3);	  CPT	  (CP,	  75	  mg/Kg	  plus	  
100	  mg/Kg	  respectively	  on	  day	  1	  plus	  T,	  60	  mg/Kg	  on	  days	  1,	  2	  and	  3).	  	  
rhApo2L/TRAIL	  schedule	  and	  dose	  were	  established	  according	  to	  previous	  
studies	  (data	  on	  file,	  Amgen	  Inc,	  Thousand	  Oaks,	  CA/Genentech	  Inc,	  South	  
San	  Francisco,	  CA,	  2009).	  	  
Tumor	   volumes	   were	   measured	   with	   a	   caliper	   every	   third	   day;	   volumes	  
were	   calculated	   using	   the	   modified	   ellipsoidal	   formula:	   1/2(length	   x	  
width2).	   Mice	   were	   suppressed	   at	   the	   21th	   day	   or	   when	   tumor	   volume	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reached	  500	  mm3.	  Delta	  volume	  was	  calculated	  by	  the	  following	  formula:	  
(tumor	  volume	  at	  the	  day	  n-­‐	  tumor	  volume	  at	  the	  day	  1)/tumor	  volume	  at	  
the	  day	  1*100.	  
4.1.7.2.	  rhAPO2L/TRAIL	  plus	  RG7112	  
30	   SCID	   mice	   at	   the	   6th	   week	   were	   intraperitoneally	   (IP)	   injected	   with	  
5x106	   ZL34	   cells	   previously	   transduced	  with	   lentiviral	   vector	   containing	   a	  
plasmid	   encoding	   for	   Luciferase.	   3	   weeks	   post	   injection	   the	   mice	   were	  
randomized	   in	  4	   treatment	  groups	  and	   treated	  with	  RG7112	   (Hoffman-­‐La	  
Roche	  Inc.)	  or	  vehicle	  (days	  1-­‐21)	  by	  gavage	  and/or	  rhAPO2L/TRAIL	  (days	  1-­‐
3)	  by	  IP.	  Tumor	  size	  was	  assessed	  once	  a	  week	  by	  in	  vivo	  bioluminescence	  
using	  Xenogen	  bioluminescence	   imaging	  after	   IP	   injection	  of	  D-­‐luciferin	   in	  
each	  mouse.	  The	  mice	  were	  suppressed	  at	  the	  22th	  day.	  Average	  Radiance	  
[p/s/cm²/sr]	  was	  proportional	   to	   the	  number	  of	  ZL34	  cells	  expressing	   the	  
LUC	  gene	  and	  D	  Average	  radiance	  was	  used	  as	   indicator	  of	  tumor	  growth	  
and	  calculated	  by	   the	   following	   formula:	   (Average	  Radiance	  at	   the	  day	  n-­‐	  
Average	  Radiance	  at	  the	  day	  1)/Average	  radiance	  at	  the	  day	  1.	  
4.2	   Translational	   study	   of	   the	   identification	   of	   pathological	   and	   molecular	  
differences	  in	  chemonaive	  tumor	  samples	  from	  different	  MPM	  histologic	  
subtypes	  (epithelioid	  versus	  non-­‐epithelioid)	  
4.2.1	  Patients	  samples	  and	  data	  collection	  
We	   retrospectively	   collected	   and	   analyzed	   epithelioid,	   biphasic	   and	  
sarcomatoid	  malignant	  pleural	  mesothelioma	  samples	  from	  the	  diagnostic	  
biopsy.	   In	   order	   to	   perform	   RT-­‐qPCR	   and	   immunohistochemistry	   the	  
following	  tumor	  samples	  were	  required:	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-­‐	   1	   hematoxylin	   and	   eosin	   stained	   slide	   and	   paraffin-­‐embedded	   tumor	  
block	   or	   5-­‐10	   paraffin	   embedded	   tumor	   sections	   in	   IHC	   slides	   (for	  
immunohistochemistry	  analysis)	  
-­‐	   paraffin	   embedded	   tumor	   block	   or	   5	   sections	   (10	   u)	   in	   eppendorf	  
RNASE/DNASE	  free	  (for	  RT-­‐qPCR).	  
All	   the	   samples	   (N=38)	   were	   analyzed	   for	   protein	   expression	   levels	   of	  
MDM2	  and	  HIF1alpha	  through	  IHC	  and	  for	  inflammation,	  necrosis	  and	  Ki67	  
levels;	   mRNA	   expression	   levels	   of	   MDM2	   and	   HIF1alpha	   levels	   were	  
quantified	   through	   RT-­‐qPCR	   in	   32	   tumor	   samples	   (20	   epithelioid	   and	   12	  
sarcomatoid/biphasic)	   where	   RNA	   was	   available.	   VEGF	   IHC	   and	   RT-­‐qPCR	  
analysis	   were	   performed	   in	   a	   training	   set	   of	   27	   tumor	   samples	   (17	  
epithelioid	   and	   10	   sarcomatoid/biphasic).	   As	   negative	   controls	   we	   used	  
normal	  pleural	  from	  4	  non	  cancer	  patients	  undergoing	  thoracic	  surgery.	  
Complete	   clinical	   information	   about	   patients	   enrolled	   in	   the	   study	   were	  
collected:	  age,	  gender,	  ECOG	  PS,	  EORTC	  score,	  stage,	  systemic	  treatments,	  
surgery,	   radiotherapy,	   first	   progression	   and	   last	   follow-­‐up	   date,	   status	  
(alive/dead).	  
To	   perform	   the	   statistical	   analyses,	   all	   data	   collected	  were	   recorded	   in	   a	  
computer	  data	  base	  (Microsoft	  Excel)	  with	  a	  protection	  of	  password.	  
We	   collected	   the	   informed	   consent	   to	   the	   data	   processing	   of	   the	   data	  
subjects	  included	  in	  the	  research	  if,	  during	  the	  study,	  it	  was	  possible	  to	  give	  
them	   the	   information	   and	   to	   get	   the	   related	   consent,	   and	   in	   particular,	  
when	   they	   turned	   to	   our	   Institute	   also	   for	   follow	   up	   reasons.	   The	  
operations	   of	   collection,	   storage,	   preservation,	   and	   circulation	   of	   the	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biological	   samples	  as	  well	  as	  all	   the	  data	  processing	  operations	   regarding	  
health	   data	   of	   the	   persons	   involved	   in	   the	   study	  were	   uniformed	   to	   the	  
security	  and	  organizational	  measures	  defined	  in	  the	  document	  “Guidelines	  
on	  data	  protection	  in	  medical	  and	  biomedical	  research”.	  	  
Eight	   slices	   of	   10	  μm	   sections/sample	  have	  been	   collected	   in	   1,5	  ml	   of	   a	  
microcentrifuge	  tube	  and	  incubated	  in	  xylene	  at	  elevated	  temperatures	  to	  
solubilize	   and	   remove	   paraffin	   from	   the	   tissue,	   then	   washed	   in	   alcohol	  
solutions	  to	  remove	  the	  xylene.	  Total	  RNA	  extraction	  of	  the	  deparaffinized	  
samples	  have	  been	  performed	  using	  RecoverAll	  Total	  Nucleic	  Acid	  Isolation	  
Kit	  (Ambion)	  according	  to	  manufacturer’s	  protocol.	  
4.2.2	  mRNA	  expression	  analysis.	  
Reverse	  transcription	  of	   total	  mRNA	  was	  performed	  using	  500	  ng	  of	   total	  
RNA/sample	  by	   SuperScript	   II	   Reverse	  Trancriptase	   (Invitrogen)	   according	  
to	  the	  manufacturer’s	  protocol.	  Quantitative	  analysis	  of	  MDM2,	  VEGF,	  and	  
HIF-­‐1	  alpha	  genes	  have	  been	  performed	  by	  LightCycler	  480	  Real	  time	  PCR	  
System	  and	  LightCycler	  480	  SYBR	  Green	  I	  Master	  Mix	  (Roche)	  according	  to	  
the	  manufacturer’s	  protocol	  using	  specific	  primers	  for	  each	  genes	  (Sigma).	  
As	   internal	   reference	  we	  used	  B2-­‐microglobulin,	  GAPDH	  and	  b-­‐actin.	   The	  
Real	  Time	  reaction	  was	  carried	  out	  as	  follows:	  95°C	  for	  5	  min,	  40	  cycles	  of	  
95°C	  for	  10	  s,	  60°C	  for	  10	  s,	  and	  72°C	  for	  10	  s.	  All	  reaction	  have	  been	  run	  in	  
triplicate	   and	   the	   quantitation	   of	   gene	   expression	   performed	   using	   the	  
∆∆CT	  calculation	  as	  previously	  described.	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4.2.3	  Immunohistochemistry	  and	  pathologic	  assessment	  
Serial	  sections	  of	  4	  micron	  were	  immunostained	  with	  the	  monoclonal	  Ki67,	  
MDM2,	  HIF	  1alpha	  and	  VEGF	  antibodies.	  The	  strong	  dark	  stained	  Ki67	  and	  
MDM2	  and	  HIF1alpha	  nuclei	  were	  counted	  and	  expressed	  as	  %	  of	  total	  cell	  
number.	  The	  counting	  of	  VEGF	  positive	  cells	  was	  based	  on	  the	  number	  and	  
staining	  intensity	  of	  positive	  cells	  (from	  0	  to	  300).	  The	  presence	  of	  necrosis	  
and	   inflammation	   were	   evaluated	   on	   hematoxylin	   eosin	   sections	   and	  
quantified	  using	  a	  score	  system	  from	  0	  to	  3	  (0:	  absent;	  1:	  <10%;	  2	  from	  10	  
to	  20%	  and	  3>20%	  of	  the	  whole	  tumor	  section	  examined).	  
4.3.	  Statistics	  
4.3.1	  Preclinical	  studies	  
In	   vitro	   and	   in	   vivo	   studies	   results	   were	   expressed	   as	   mean	   +/-­‐	   standard	  
error	   and	   +/-­‐	   standard	   deviation,	   respectively.	  Mann	  Whitney	   and	  ANOVA	  
test	   (followed	   by	   post-­‐hoc	   LSD	   test)	   were	   used	   to	   compare	   different	  
treatment	   groups	   in	   vitro	   and	   in	   vivo,	   respectively.	   A	   p	   value	   ≤	   0,05	   was	  
considered	  as	  significant.	  	  
4.3.2	  Translational	  studies	  
Low	   versus	   high	   expression	   levels	   of	   each	   marker	   and	   pathological	  
parameter	  have	  been	  identified	  over	  and	  under	  the	  median	  value,	  and	  data	  
presented	   as	   %	   of	   patients	   with	   high/low	   expression	   levels	   in	   each	  
histological	  subtype.	  Kruskall-­‐Wallis	  test	  have	  been	  performed	  to	  evaluate	  a	  
different	   expression	   of	   molecular	   markers	   and	   pathological	   parameters	   in	  
the	   two	   main	   histological	   subtypes,	   and	   to	   assess	   different	   pathological	  
features	   in	   tumor	   tissues	  with	  high/low	  MDM2	  expression.	  The	  correlation	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between	  MDM2	  and	  HIF1alpha	   expression	   levels	   (and	   possibly	   VEGF),	   and	  
between	   RNA	   and	   protein	   expression	   levels	   of	   each	   marker	   have	   been	  
investigated	  through	  the	  linear	  correlation	  analysis	  of	  Spearman.	  Overall	  and	  
progression	   free	   survival	   curves	   have	   been	   designed	   according	   to	   Kaplan-­‐
Meier	  method.	  	  
The	   univariate	   analysis	   allowed	   to	   select	   the	   molecular	   marker	   and/or	  
morphological	   parameter	   to	   be	   analyzed	   with	   the	   clinical	   features	   in	   the	  
multivariate	  analysis	   for	   the	  assessment	  of	   the	   impact	  on	  PFS	  and	  OS	   (Cox	  
Regression	  Proportional	  Hazards	  Model).	  
PFS	   has	   been	   assessed	   from	   the	  date	   of	   enrolment	   to	   the	  date	   of	   disease	  
progression	  to	  the	  first-­‐line	  (or	  relapse)	  or	  to	  the	  date	  of	  death,	  whichever	  
occurred	  first.	  OS	  has	  been	  assessed	  from	  the	  date	  of	  enrolment	  to	  the	  date	  
of	  death.	  
5. Results	  
5.1 Preclinical	   evaluation	   of	   the	   anticancer	   activity	   of	   rhApo2L/TRAIL	   in	  
combination	   with	   chemotherapy	   (carboplatin	   plus	   pemetrexed)[100]	   or	  
p53-­‐MDM2	  inhibitor	  RG7112	  	  
5.1.1	   rhApo2L/TRAIL	   triggers	   apoptosis	   in	   MPM	   cells	   but	   not	   in	   normal	  
cells.	  
The	   induction	   of	   apoptosis	   by	   rhApo2L/TRAIL	   treatment	   was	   tested	   in	  
seven	  MPM	  cell	  lines	  (3	  epithelioid:	  ZL55,	  H28,	  M14K;	  1	  sarcomatoid:	  ZL34;	  
3	  biphasic:	  MSTO-­‐211,	  SPC111,	  ZL5)	  and	  one	  short-­‐term	  primary	  culture	  of	  
sarcomatoid	  MPM	  cells	  established	  from	  a	  patient	  (MPM1801).	  Cells	  were	  
treated	   with	   50	   ng/ml	   rhApo2L/TRAIL	   for	   24	   hours	   and	   apoptosis	   was	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measured	   by	   Annexin	   V	   staining	   and	   Fluorometric	   Homogenous	   Caspase	  
Assays.	  The	  results	  showed	  a	  significant,	  even	  if	  heterogeneous	  sensitivity	  
of	   MPM	   cells	   to	   TRAIL	   treatment,	   independent	   from	   the	   histotype.	  
Interestingly,	  this	  effect	  was	  specific	  in	  MPM	  cells,	  as	  significant	  death	  was	  
not	  observed	  in	  control	  cells	  (HFF	  and	  PBMC)(Figure	  1a	  and	  b).	  
5.1.2	   Carboplatin	   and	   Pemetrexed	   or	  Nutlin3a	   enhance	   the	   pro-­‐apoptotic	  
effects	  of	  rhApo2L/TRAIL	  on	  MPM	  cell	  lines	  	  
As	  Carboplatin	  and	  Pemetrexed	  (CP)	  are	  the	  cornerstone	  of	  current	  MPM	  
therapies,	   we	   next	   tested	   whether	   these	   drugs	   might	   synergize	   with	  
rhApo2L/TRAIL	   (T).	   Apoptosis	   was	   measured	   by	   Annexin	   V	   staining	   and	  
flow	  cytometry.	  Cell	  lines	  ZL34	  and	  ZL55	  were	  selected	  as	  representative	  of	  
sarcomatoid	   and	   epitheliod	   MPM,	   respectively.	   Results	   showed	   a	  
significant	  (p	  <	  0.001)	  synergistic	  effect	  of	  the	  combination	  of	  these	  drugs	  
compared	  with	  no	   treatment	  or	  with	  CP	  or	  T	  as	   single	  agents	   (Figure	  2	  a	  
and	   c).	   These	   results	   were	   also	   confirmed	  when	   apoptosis	   was	   assessed	  
with	   the	  caspases	  assay	   (Figure	  2b).	  A	   similar	  effect	  was	   shown	   in	  all	   the	  
tested	   cell	   lines	   (3	   epithelioid,	   3	   biphasic	   and	   1	   sarcomatoid)	   and	   in	   the	  
sarcomatoid	  primary	  culture	  (Figure	  3).	  
Previous	   studies	   [49]	   suggested	   that	   sensitivity	   to	   TRAIL	   might	   be	  
dependent	  on	  the	  levels	  of	  reactive	  oxygen	  species	  (ROS).	  However,	  we	  did	  
not	  observe	  any	  difference	  in	  specific	  cell	  death	  when	  both	  ZL34	  and	  ZL55	  
cell	  lines	  were	  treated	  with	  the	  ROS	  scavenger	  NAC	  (Figure	  4).	  
We	   then	   analyzed	   in	   vitro	   effects	   of	   rhAPO2L/TRAIL	   plus	   the	  MDM2-­‐p53	  
inhibitor	   Nutlin3a	   by	   Annexin	   V	   and	   Caspases	   assay.	   Apoptosis	   assay	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performed	   in	   eight	   MPM	   cell	   lines,	   representing	   the	   three	   different	  
histotypes	   (epithelioid,	   biphasic	   and	   sarcomatoid),	   showed	   a	   synergistic	  
anticancer	  effect	  of	  Nutlin3a	  plus	  rhAPO2L/TRAIL.	  Higher	  synergistic	  effect	  
was	  shown	  in	  sarcomatoid	  cell	  (Figure	  2d).	  
5.1.3	   p53	   activation	   by	   Carboplatin	   and	   Pemetrexed	   sensitizes	   to	   TRAIL-­‐
dependent	  apoptosis	  in	  vitro	  
We	  next	   investigated	   the	  mechanisms	  at	   the	  basis	  of	   the	   sensitization	   to	  
TRAIL-­‐dependent	   apoptosis	   induced	   by	   CP.	   Considering	   that	   both	  
Carboplatin	   and	   Pemetrexed	   induced	   DNA	   damage	   resulting	   in	   p53	  
activation	  and	  that	  p53	  is	  not	  mutated	  in	  most	  MPM	  cases,	  we	  tested	  the	  
effect	  of	  CP	  on	  p53	  levels	  in	  the	  ZL55	  and	  ZL34	  cell	  lines.	  Results	  indicated	  
an	  increase	  in	  p53	  levels	  in	  ZL55	  and	  ZL34	  cell	  lines	  following	  CP	  treatment	  
(Figure	   5a).	   To	   test	   whether	   this	   increase	   in	   p53	   levels	   accounts	   for	   the	  
ability	   of	   CP	   to	   sensitize	   to	   TRAIL-­‐induced	  apoptosis,	  we	   investigated	   cell	  
death	  in	  ZL55	  and	  ZL34	  cell	  lines	  treated	  with	  CP	  and/or	  T	  after	  p53	  knock–
down	  by	  siRNAs.	  Results	  demonstrated	  that	  the	  siRNA	  treatment	  induced	  a	  
significant,	   specific	   knock-­‐down	   of	   p53	   expression	   (Figure	   5a	   and	   b).	  
Interestingly,	  p53	  silencing	  resulted	  in	  a	  significant	  reduction	  of	  cell	  death	  
induced	  by	  CP	  and	  T	   (Figure	  5c);	   importantly,	   this	  effect	  was	   reverted	  by	  
cotransfection	   with	   a	   vector	   coding	   for	   wild-­‐type	   p53	   (Figure	   5c).	   We	  
observed	   no	   or	   weak	   p53	   expression	   in	   five	   tumor	   tissues	   from	   MPM	  
patients;	   in	   contrast,	   p53	  was	   readily	   detected	   in	   the	   ZL34	   and	   ZL55	   cell	  
lines	  after	  p53	  vector	  (Figure	  5b).	  
5.1.4	  p53	  activation	  increases	  the	  expression	  of	  TRAIL	  receptors	  in	  vitro	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To	   explore	   the	   TRAIL-­‐sensitizing	   effect	   of	   p53	   activation,	   we	   next	  
investigated	  whether	  p53-­‐inducing	   treatments	  enhance	   the	  expression	  of	  
the	   TRAIL	   receptors	   DR4/DR5,	   DcR1/DcR2.	   Results	   showed	   that	   the	   ZL55	  
and	  ZL34	  cell	   lines	  expressed	  higher	  levels	  of	  DR4	  and	  DR5	  in	  response	  to	  
CP	   treatment	   (Figure	   6a).	   Interestingly,	   knock-­‐down	   of	   p53	   expression	  
resulted	  in	  a	  significant	  reduction	  of	  CP-­‐induced	  DR4	  and	  DR5	  expression	  in	  
MPM	  cells	   (p<	  0.05),	  while	  no	   reduction	  of	  DR4	  and	  DR5	  expression	  was	  
observed	   in	  MPM	   cells	   cotransfected	   with	   the	   p53	   siRNA	   plus	   wild-­‐type	  
p53	   expression	   vector	   (Figure	   7).	   Taken	   together,	   these	   data	   provide	  
evidence	  of	  a	  causal	  link	  between	  CP	  treatment,	  p53	  activation,	  increased	  
expression	   of	   DR4	   and	   DR5	   receptors	   and	   sensitivity	   to	   TRAIL.	   The	  
detection	  of	  DcR1	  and	  DcR2	  levels	  in	  ZL34	  and	  ZL55	  cell	  lines	  treated	  or	  not	  
with	  CP	  seemed	  not	  relevant.	  
When	  we	  explored	  the	  mechanism	  at	  the	  basis	  of	  the	  synergism	  between	  
rhAPO2L/TRAIL	   and	   Nutlin3a	   in	   sarcomatoid	   cell	   lines,	   we	   observed	   the	  
activation	  of	  p53,	  confirmed	  also	  by	  the	  activation	  of	  the	  two	  p53	  targets	  
p21	   and	   inhibition	   of	   surviving.	   Additionally,	   p53	   activation	   by	   Nutlin3a	  
increased	  the	  expression	  of	  DR4/DR5	  TRAIL	  death	  receptors	  (Figure	  6b).	  
5.1.5	   Antitumor	   activity	   of	   Apo2L/TRAIL	   +	   chemotherapy	   or	   RG7112	   in	  
preclinical	  animal	  models	  of	  MPM	  
To	   test	   the	   in	   vivo	   efficacy	   of	   Apo2L/TRAIL	   as	   single	   agent	   and	   in	  
combination	   with	   CP,	   we	   employed	   a	   preclinical	   model	   based	   on	   the	  
subcutaneous	  injection	  of	  the	  ZL55	  and	  ZL34	  MPM	  cell	  lines	  in	  SCID	  mice.	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Thirty	   SCID	   mice	   were	   inoculated	   with	   ZL55	   and	   30	   SCID	   mice	   were	  
inoculated	  with	  ZL34	  cells.	  Twenty-­‐four	  mice	  had	  a	  measurable	  tumor	  and	  
were	   randomized	   in	   the	   four	   treatment	   groups	   (N=6/group).	   Mice	  
inoculated	   with	   ZL55	   cells	   showed	   a	   statistically	   significant	   reduction	   of	  
tumor	   volume	   at	   every	   time	   point	   in	   the	   three	   treatment	   groups	   (CP;	   T;	  
CPT)	   compared	   to	   not	   treated	   (NT)	   mice;	   moreover,	   tumor	   volume	   was	  
significantly	  reduced	  in	  mice	  treated	  with	  CPT	  compared	  to	  CP	  at	  the	  21th	  
day	  (p<	  0.05)	  (Figure	  8a).	  
Mice	  inoculated	  with	  ZL34	  cells	  showed	  a	  statistically	  significant	  reduction	  
of	   tumor	   volume	   at	   every	   time	   point	   in	   T	   and	   CPT	   treatment	   groups	  
compared	   to	   not	   treated;	   at	   the	   day	   21	   we	   observed	   a	   statistically	  
significant	  difference	  of	  tumor	  volume	  between	  all	  three	  treatment	  groups	  
and	  untreated	  mice	  and	  between	  CPT	  and	  CP	  groups	  (Figure	  8b).	  
No	   significant	   difference	   was	   observed	   between	   mice	   treated	   with	   CP	  
compared	  to	  T	  (Figures	  8	  a,b).	  
To	  test	  the	  in	  vivo	  efficacy	  of	  Apo2L/TRAIL	  in	  combination	  with	  RG7112,	  we	  
employed	   a	   preclinical	   model	   based	   on	   the	   intraperitoneal	   injection	   of	  
ZL34	  MPM	  cell	  lines	  in	  SCID	  mice.	  30	  SCID	  mice	  were	  inoculated	  with	  ZL34	  
cells.	  
Tumor	  growth	  in	  mice	  injected	  with	  ZL34	  cells	  was	  significantly	  reduced	  in	  
mice	  treated	  with	  RG7112	  plus	  rhApo2L/TRAIL	  compared	  with	  mice	  treated	  
with	  RG7112	  or	  Apo2L/TRAIL	  as	  single	  agents	  (Figure	  9).	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5.2 Translational	   study	   of	   the	   identification	   of	   pathological	   and	   molecular	  
differences	  in	  chemonaive	  tumor	  samples	  from	  different	  MPM	  histologic	  
subtypes	  (epithelioid	  versus	  non-­‐epithelioid)	  
Formalin-­‐fixed	   paraffin	   embedded	   tumor	   samples	   from	   Video-­‐Assisted	  
Thoracic	   Surgery	   (VATS)-­‐guided	   pleural	   biopsies	   of	   38	   treatment-­‐naive	  
MPM	   patients	   who	   were	   referred	   to	   our	   Center	   for	   diagnosis	   and	  
treatment	   over	   the	   years,	   were	   collected	   and	   analyzed.	   Our	   case	   series	  
included	   25	   epithelioid,	   7	   biphasic	   and	   6	   sarcomatoid	   mesothelioma	  
samples	   (25	   epithelioid	   and	   13	   non-­‐epithelioid).	   The	   last	   patient	   was	  
included	   in	   November,	   30th	   2014;	   all	   alive	   patients	   were	   censored	   for	  
survival	  analysis	   in	  December,	  15th	  2014.	   In	  5	  patients	  no	  survival	  follow-­‐
up	  was	  available.	  Patients’	  clinical	  features	  are	  summarized	  in	  Table	  1.	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5.2.1	  MDM2,	  HIF1alpha,	  VEGF	  expression	   levels	   in	   epithelioid	   versus	  non-­‐
epithelioid	  MPM	  samples	  
Nuclear	   expression	   of	   MDM2	   and	   HIF1alpha	   was	   higher	   in	  
sarcomatoid/biphasic	  tumor	  samples	  (77%	  and	  77%	  of	  tumor	  samples)	  and	  
lower	  in	  epithelioid	  samples	  (68%	  and	  64%	  of	  tumor	  samples,	  respectively);	  
similar	   results	   were	   observed	   when	   we	   investigated	   mRNA	   expression	  
levels	   of	  MDM2	   but	   not	   of	   HIF1alpha	   (Table	   2	   and	   3).	   No	   expression	   of	  
MDM2	  and	  HIF1alpha	  was	  observed	  in	  normal	  pleura	  samples.	  
Higher	   MDM2	   and	   HIF1alpha	   IHC	   expression	   levels	   were	   significantly	  
associated	   with	   sarcomatoid/biphasic	   histologic	   subtype	   (p=0.010	   and	  
p=0.007,	   respectively)	   (Figure	   10	   and	   11).	   When	   we	   analyzed	   mRNA	  
expression	  levels	  of	  MDM2	  we	  observed	  a	  correlation	  trend	  with	  histologic	  
subtype	   (higher	   levels	   in	   sarcomatoid/biphasic	   samples),	   although	   not	  
statistically	   significant	   (p=0.067);	   no	   correlation	   was	   observed	   between	  
HIF1alpha	   mRNA	   expression	   levels	   and	   histologic	   subtype	   (p=0.2),	   and	  
between	   RNA	   and	   protein	   expression	   levels	   of	   MDM2(p=0.3)	   and	  
HIF1alpha	  (p=0.9).	  
Among	  the	  18	  tumor	  samples	  with	  high	  MDM2	  expression	  at	  the	  IHC,	  only	  
9	   showed	   high	   levels	   of	   mRNA	   expression	   at	   the	   RT-­‐qPCR	   analysis,	  
suggesting	   mechanisms	   other	   than	   gene	   amplification	   sustaining	   protein	  
overexpression.	  
Importantly,	   when	   we	   assessed	   the	   correlation	   between	   nuclear	   IHC	  
expression	   levels	   of	   MDM2	   and	   HIF1alpha,	   we	   observed	   a	   statistically	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significant	   positive	   correlation	   (correlation	   coefficient=0.533;	   p	   value=	  
0.00626).	  	  
No	  significant	  difference	  between	  the	  two	  main	  histologic	  subgroups	  was	  
observed	  when	  we	  analyzed	  VEGF	  protein	  and	  mRNA	  expression	   levels	   in	  
the	   training	   set	   of	   27	   tumor	   samples	   (Table	   4),	   therefore	  we	   considered	  
this	  marker	  not	  worthy	  of	   further	   investigation	   through	  either	   IHC	  or	  RT-­‐
qPCR.	  Moreover,	  VEGF	  expression	  was	  not	  completely	  negative	   in	  normal	  
pleural	  samples,	  probably	  because	  of	  a	  consequence	  of	  a	  pro-­‐inflammatory	  
phenotype	  of	  such	  controls.	  
5.2.2	   Inflammation,	   necrosis	   and	   proliferation	   index	   levels	   in	   epithelioid	  
versus	  non-­‐epithelioid	  MPM	  samples	  
When	   we	   investigated	   different	   pathological	   features	   in	   tumor	   samples	  
and	   compared	   epithelioid	   and	   sarcomatoid/biphasic	   subtypes,	   we	  
observed	   more	   frequently	   low	   levels	   of	   inflammation	   in	   sarcomatoid	  
samples	   (62%	   of	   tumor	   samples)	   and	   low	   levels	   of	   necrosis	   among	  
epithelioid	   tumor	   samples	   (72%	   of	   tumor	   samples).	   Differently,	  
proliferation	   index	  was	  more	  frequently	   low	  in	  epithelioid	  (72%)	  and	  high	  
in	  sarcomatoid/biphasic	  (77%)	  samples	  (Table	  5).	  No	  statistically	  difference	  
in	   terms	   of	   inflammation	   (p=0.112)	   and	   necrosis	   (p=0.07)	   levels	   was	  
observed	   between	   epithelioid	   and	   sarcomatoid/biphasic	   samples	   (Figure	  
12	   a,b	   and	   d);	   proliferation	   index	   was	   significantly	   higher	   in	  
sarcomatoid/biphasic	  compared	  with	  epithelioid	  samples	  (p=0.005)	  (Figure	  
12	  c	  and	  d).	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When	   we	   divided	   the	   whole	   patients	   population	   in	   two	   subgroups	  
according	   to	   different	   MDM2	   expression	   levels	   (high	   versus	   low),	   we	  
observed	   that	   proliferation	   index	   was	   also	   significantly	   higher	   in	   tumor	  
samples	  with	  higher	  MDM2	  expression	  (p=0.008,	  data	  not	  shown).	  
5.2.3	   Exploratory	   endpoints:	   prognostic	   and	   predictive	   role	   of	   MDM2	  
expression	  levels	  and	  other	  markers/histological	  features	  	  
As	   exploratory	   analysis,	   we	   assessed	   the	   impact	   of	   some	   clinical	   and	  
pathological	  features	  on	  OS	  and	  PFS.	  Unfortunately,	  5	  patients	  were	  lost	  to	  
follow-­‐up	   and	   no	   survival	   data	  were	   available,	   thus	   reducing	   the	   sample	  
size	   and	   impairing	   this	   analysis.	   Moreover,	   other	   weak	   points	   were	   that	  
some	   sarcomatoid/biphasic	   mesothelioma	   patients	   had	   no	   sufficient	  
follow-­‐up	   time	   (less	   than	   6	   months)	   and	   different	   local	   or	   systemic	  
treatments	  were	  considered.	  	  
No	  statistically	  significant	  difference	   in	  terms	  of	  OS	  (p=0.3)	  or	  PFS	  (p=0.7)	  
was	   observed	   between	   epithelioid	   and	   sarcomatoid/biphasic	   samples,	  
even	   if	   a	   trend	   towards	   a	   longer	  OS	  and	  PFS	  was	  observed	   in	  epithelioid	  
(median	   OS	   80	   weeks;	   median	   PFS	   48	   weeks)	   compared	   with	  
sarcomatoid/biphasic	  MPM	  (median	  OS	  56	  weeks;	  median	  PFS	  40	  weeks)	  
(Figure	  13).	  No	  statistically	  significant	  difference	  in	  terms	  of	  OS	  (p=0.5)	  or	  
PFS	   (p=0.3)	   between	   high	   and	   low	   MDM2-­‐expressing	   samples	   was	  
observed.	  A	  trend	  towards	  a	  longer	  OS	  and	  PFS	  was	  seen	  in	  samples	  with	  
lower	   MDM2	   expression	   levels	   (median	   OS	   96	   weeks;	   median	   PFS	   48	  
weeks)	  compared	  with	  sarcomatoid/biphasic	  MPM	  (median	  OS	  60	  weeks;	  
median	  PFS	  36	  weeks).	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Finally	   we	   analyzed	   the	   impact	   of	   different	   clinical	   (EORTC	   prognostic	  
score,	   gender,	   histology,	   surgery,	   subsequent	   chemotherapy	   lines)	   and	  
pathological	   features	   (inflammation,	   necrosis,	   proliferation	   index)	   and	  
marker	   expression	   levels	   (MDM2	   and	   HIF1alpha)	   on	   OS	   and	   PFS	   in	   a	  
multivariate	  analysis:	  we	  observe	  no	  significant	  impact	  of	  any	  covariate	  on	  
OS,	  while	  proliferation	  index	  significantly	  influences	  PFS	  (p=	  0.007).	  
The	  results	  of	  this	  exploratory	  analysis	  might	  be	  read	  with	  caution	  due	  to	  
the	   small	   number	   of	   patients,	   the	   heterogeneity	   of	   local	   and	   systemic	  
treatment	   and	   the	   insufficient	   follow-­‐up	   for	   a	   consistent	   part	   of	  
sarcomatoid/biphasic	   MPM	   patients.	   Future	   investigation	   in	   a	   wider	  
sample	  size	  is	  warranted.	  
	  
6. Discussion	  	  
Malignant	  pleural	  mesothelioma	  shows	  high	  refractoriety	  to	  chemotherapy	  and	  
radiotherapy,	   thus	   median	   overall	   survival	   and	   progression	   free	   survival	   are	  
about	  12	  and	  6	  months	   respectively	   in	  patients	  not	  eligible	   for	   surgery.	  Since	  
2003,	  when	   antifolate	   agents	  were	   introduced	   in	   the	   clinical	  management	   of	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this	  disease,	  the	  gold	  standard	  chemotherapy	  is	  a	  Platinum-­‐based	  doublet	  plus	  
Pemetrexed	  or	  Raltitrexed[1,	  2].	  Surgery	  is	  feasible	  in	  highly	  selected	  cases,	  and	  
patients	  suitable	  for	  trimodal	  treatment	  (neoadjuvant	  chemotherapy,	  surgery,	  
postoperative	   radiotherapy)	   achieve	   overall	   survival	   longer	   than	   25	   months	  
[28].	   After	   the	   standard	   first-­‐line	   Pemetrexed/Platinum	   combination	   there	   is	  
not	  a	  defined	  regimen	  for	  the	  second	  line	  treatment	  of	  MPM,	  and	  the	  clinical	  
benefits	   are	   uncertain[101-­‐104].	   Recent	   studies	   tested	   biologic	   agents	   that	  
target	   key	   oncogenic	   pathways,	   including	   phosphatidylinositol3-­‐kinase	  
(PI3K)/mammalian	   target	   of	   Rapamycin	   (mTOR)	   pathways,	   histone	  
deacetylases	  (HDAC),	  Nuclear	  Factor	  kB	  (NFkB)	  and	  neoangiogenesis.	  However,	  
no	  one	  of	  these	  therapies	  proved	  to	  significantly	  impact	  the	  natural	  history	  of	  
this	  neoplasm,	  thus	  reinforcing	  the	  need	  for	  new	  drugs	  to	  improve	  prognosis	  of	  
MPM	  patients.	  
TRAIL	   is	   a	  member	   of	   the	   TNF	   superfamily	  which	   has	   recently	   emerged	   as	   a	  
potentially	   interesting	  anticancer	  agent	  because	  of	   its	  ability	  to	  kill	  cancer	  cell	  
lines	  while	  sparing	  many	  normal	  cells[40,	  55,	  105].	  Several	  studies	  showed	  that	  
MPM	   cells	   are	   resistant	   to	   TRAIL	   in	   vitro,	   although	   this	   resistance	   can	   be	  
overcome	   by	   combining	   chemotherapy	   with	   alpha-­‐tocopherylsuccinate,	  
anisomycin,	  HDAC	  inhibitors,	  proteasome	  inhibitors	  and	  FLIP	  siRNA	  [49,	  60,	  61,	  
106-­‐109].	   Increased	   apoptotic	   levels	   were	   demonstrated	   in	   four	   cell	   lines	  
treated	   with	   the	   association	   of	   TRAIL	   and	   chemotherapy	   (Cisplatin,	  
Doxorubicin,	   Gemcitabine	   or	   Etoposide),	   probably	   through	   p53-­‐independent	  
apoptotic	   pathway;	   no	   DR5	   increase	   was	   observed	   at	   the	   basis	   of	   this	  
sensitization[60].	  Recently,	  another	  study	  showed	  apoptotic	  effects	  of	  TRAIL	  or	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the	  monoclonal	  antibodies	  Mapatumumab	  and	  Lexatumumab	  directed	  against	  
DR4	   and	   DR5	   on	   13	   MPM	   cell	   lines;	   this	   effect	   was	   enhanced	   by	   Cisplatin	  
probably	   trough	   the	   induction	   of	   ROS	   [49].	   Other	   studies	   showed	   a	   p53-­‐
dependent	   induction	   of	   DR4	   and	   DR5	   expression	   by	   Alpha-­‐tocopheryl	  
succinate,	   resulting	   in	   TRAIL	   sensitization	   [61].	   While	   TRAIL-­‐dependent	  
apoptosis	  is	  thought	  to	  be	  p53-­‐independent,	  p53	  wild	  type	  cancer	  cells	  can	  be	  
sensitized	   to	   TRAIL	   through	   p53	   activation	   [62].	   In	   contrast	   to	   most	   solid	  
tumors,	  MPM	  cells	  frequently	  express	  wild	  type	  p53	  [63].	  	  
Recombinant	  human	  (rh)	  Apo2L/TRAIL	  (Dulanermin),	  a	  receptor	  agonist	  which	  
binds	  both	  DR4	  and	  DR5[53,	  54],	   showed	  antitumor	  activity	   in	   in	   vitro	   and	   in	  
vivo	   tumor	   models	   of	   different	   cancer	   types	   both	   as	   single	   agent	   and	   in	  
combination	  with	   chemotherapy	  without	   any	   toxicity	   in	   normal	   cells	   [55-­‐57],	  
and	  was	  the	  first	  TRAIL	  agonist	  investigated	  in	  human	  clinical	  trials	  [51,	  52,	  58].	  
In	   the	   present	   study	   we	   investigated	   proapoptotic	   effects	   of	   rhApo2L/TRAIL	  
combined	   to	   different	   intrinsic	   apoptosis	   triggers:	   first	   the	   DNA-­‐damaging	  
agents	   Carboplatin	   and	   Pemetrexed[100],	   then	   the	   p53-­‐MDM2	   inhibitor	  
nutlin3-­‐RG7112.	   To	   our	   knowledge,	   this	   is	   the	   first	   in	   vivo	   study	   of	   a	   TRAIL	  
agonist	  in	  mesothelioma.	  
We	  observed	  heterogeneous	   sensitivity	   of	   seven	  mesothelioma	   cell	   lines	   and	  
one	  primary	  culture	  to	  rhApo2L/TRAIL	  treatment;	  higher	  or	  lower	  sensitivity	  to	  
the	   TRAIL	   agonist	   did	   not	   seem	   to	   be	   dependent	   on	   the	   histologic	   subtype.	  
These	   data	   seem	   in	   line	  with	   previous	   studies	   of	   TRAIL	   agonists	   in	   vitro,	  and	  
might	  be	  explained	  by	  the	  variable	  expression	   levels	  of	  antiapoptotic	  proteins	  
such	   as	   Bcl2	   and	   IAPs-­‐family	   proteins,	   or	   other	   proteins	   involved	   in	   the	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apoptotic	   pathway[49].	   These	   proteins	   have	   been	   previously	   suggested	   as	  
useful	  predictive	  markers	  of	  sensitivity	  to	  TRAIL-­‐dependent	  apoptosis.	  
We	   observed	   higher	   apoptotic	   levels	  when	   both	   epithelioid	   and	   sarcomatoid	  
cell	   lines	   were	   treated	   with	   chemotherapy	   and	   rhApo2L/TRAIL	   compared	   to	  
Carboplatin/Pemetrexed	   and	   rhApo2L/TRAIL	   alone.	   This	   effect	   seemed	   to	   be	  
dependent	  upon	  p53	  but	  not	  on	  increased	  ROS	  levels.	  Furthermore	  we	  showed	  
that	   p53	   activation	   leads	   to	   increased	   expression	   of	   the	   DR4	   and	   DR5	  
receptors.	   Previous	   evidences	   showed	   that	   chemotherapy-­‐induced	   p53	  
activation	   lead	   to	   antiapoptotic	   proteins	   downregulation	   (such	   as	   survivin	   or	  
Mcl1)	  and	  proapoptotic	  targets	  upregulation	  (such	  as	  Bax)	  [49,	  110].	  	  
Contrary	   to	   previous	   evidences[63],	   preliminary	   data	   from	   next-­‐generation	  
sequencing	  of	   123	  MPM	  samples	   showed	   that	   p53	  was	   among	   the	   five	  most	  
frequently	   altered	   genes	   [111],	   although	   the	   overall	   frequence	   of	   such	  
mutations	   may	   be	   considered	   low.	   Our	   results	   in	   a	   primary	   culture	   of	  
sarcomatoid	  MPM	  (MPM1801)	  showed	  no	  mutation	   in	  p53	  gene.	  Thus,	  based	  
on	  our	  results,	   it	   is	   tempting	  to	  speculate	  that	  p53	  mutational	  status	   in	  MPM	  
samples	   may	   be	   a	   predictive	   marker	   of	   sensitivity	   to	   the	   combination	   of	  
chemotherapy	  and	  rhApo2L/TRAIL.	  This	  hypothesis	  will	  be	  thoroughly	  tested	  in	  
further	   studies	   in	   p53	   knock-­‐out	   models.	   In	   vivo	   studies	   showed	   that	   the	  
association	   of	   Carboplatin/Pemetrexed	   with	   rhApo2L/TRAIL	   significantly	  
reduced	  tumor	  growth	  compared	  to	  Carboplatin/Pemetrexed	  in	  both	  cell	  lines	  
tested.	   Considering	   the	   short-­‐term	   responses	   achieved	   with	   currently	   used	  
chemotherapy,	   especially	   in	   the	   neoadjuvant	   setting	   where	   tumor	   shrinkage	  
and	   distant	   relapses	   prevention	   assume	   particular	   relevance,	   the	   synergistic	  
	   55	  
effect	   of	   chemotherapy	   combined	   to	   rhApo2L/TRAIL	   might	   improve	   patients	  
prognosis.	   Moreover,	   similar	   antitumor	   effects	   of	   rhApo2L/TRAIL	   and	  
chemotherapy	   in	   vivo,	   might	   suggest	   a	   role	   for	   such	   agent	   at	   the	   disease	  
progression	  after	  the	  first	  line	  treatment,	  where	  a	  valid	  option	  is	  still	  lacking	  in	  
patients	  eligible	  for	  further	  treatments.	  
Taken	  together	  our	  findings	  suggest	  that	  rhApo2L/TRAIL	  combined	  to	  standard	  
chemotherapy	   as	   first	   line	   treatment	   and	   as	   single	   agent	   in	   the	   second	   line	  
setting	   might	   prove	   to	   be	   an	   effective	   drug	   in	   the	   treatment	   of	   MPM,	  
considering	  also	  its	  low	  toxicity	  profile.	  
On	  the	  same	  way,	  we	  adopted	  the	  combination	  of	  rhApo2L/TRAIL	  plus	  nutlin3-­‐
RG7112,	   as	   alternative	   strategy	   to	   reactivate	   p53	   thus	   sensitizing	   to	   TRAIL-­‐
dependent	   apoptosis	   in	   vitro	   and	   in	   vivo.	  Given	   the	   central	   role	   of	  MDM2	   in	  
regulating	   p53	   activity	   and	   stability,	   developing	   small-­‐molecule	   inhibitors	   of	  
MDM2	  could	  offer	  a	  novel	  approach	  to	  treating	  cancers.	  While	  nutlin3,	  the	  first	  
developed	   compound	   targeting	   the	   p53-­‐MDM2	   complex	   was	   optimal	   for	  
previous	   studies	   of	   p53	   biology,	   and	   was	   effectively	   adopted	   in	   our	   in	   vitro	  
studies,	   this	  compound	  was	  not	  optimal	   in	  clinical	  studies,	   thus	  recent	  efforts	  
lead	   to	   a	   new	   molecule	   belonging	   to	   the	   nutlin	   family	   of	   MDM2	   inhibitors,	  
RG7112,	   which	   is	   currently	   in	   clinical	   development[84]	   (clinicaltrials.gov	  
NCT00559533;	   NCT00623870).	   The	   high	   genetic	   plasticity	   characteristic	   for	  
human	   tumors,	   especially	   at	   advanced	   stages,	   increases	   the	   chances	   for	  
acquired	   resistance	   to	   most	   single	   agent	   therapies	   including	   MDM2	  
antagonists.	   Therefore,	   combination	   approaches	   to	   cancer	   therapy	   are	  
extensively	  sought.	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In	   vitro	   studies	   confirmed	   p53	   activation	   by	   nutlin3,	   with	   subsequent	  
upregulation	  of	  TRAIL	   receptors	  and	   final	   sensitization	   to	  extrinsec	  apoptosis,	  
thus	  confirming	  previous	  results	  by	  other	  groups	  [112].	  In	  vitro	  studies	  showed	  
the	  higher	  synergism	  between	  the	  two	  molecules	  in	  sarcomatoid	  cell	  lines,	  thus	  
raising	   the	   question	   about	   different	   MDM2	   expression	   levels	   in	   epithelioid	  
versus	  non-­‐epithelioid	  (sarcomatoid	  and	  biphasic)	  MPM.	  This	  scientific	  question	  
was	  someway	  reinforced	  by	  previous	  evidence	  of	  MDM2	  overexpression	  with	  
or	   without	   gene	   amplification	   in	   soft	   tissue	   sarcomas	   [70-­‐73]	   and	   by	   the	  
evidence	  of	  higher	  effectiveness	  of	  RG7112	  in	  killing	  cancer	  cells	  overproducing	  
MDM2	  protein	   as	   a	   result	   of	  MDM2	  gene	  amplification	   [85].	   Previous	   results	  
from	  our	  in	  vitro	  studies	  showed	  higher	  MDM2	  mRNA	  levels	  in	  sarcomatoid	  cell	  
lines,	   compared	  with	   epithelioid	   (Figure	   15).	   Translational	   studies	   performed	  
on	  clinical	  samples	  from	  affected	  patients	  confirmed	  these	  data.	  
Sarcomatoid/biphasic	   mesothelioma	   are	   characterized	   by	   higher	   aggressive	  
biological	  behaviour,	  higher	  resistance	  to	  systemic	  treatments,	  more	  frequent	  
distant	   spread	   and	   poor	   prognosis.	   Our	   in	   vivo	   results	   in	   the	   sarcomatoid	  
animal	   model	   showed	   remarkable	   reduction	   in	   tumor	   growth	   with	   the	  
combination	  under	  study	  (rhApo2L/TRAIL	  plus	  nutlin3-­‐RG7112).	  These	  findings	  
might	   open	   new	   scenarios	   to	   the	  medical	   treatment	   of	   such	   histologic	  MPM	  
subtype,	  with	  a	  well-­‐tolerated	  alternative	  to	  chemotherapy,	  worthy	  of	  clinical	  
investigation.	  Moreover	  a	  systemic	  targeted	  treatment	  according	  to	  a	  specific	  
mesothelioma	  histotype	  could	  be	  planned.	  
Recently	   MDM2	   disregulation	   in	   merlin-­‐deficient	   tumors	   has	   been	   reported.	  
However	   to	   best	   of	   our	   knowledge,	   different	   expression	   level	   of	   MDM2	   in	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different	  mesothelioma	  histotypes	  have	  not	  been	   investigated,	   so	   far.	  On	   the	  
same	   way,	   specific	   morphological	   features	   (inflammation,	   necrosis,	  
proliferation	   index)	   have	   not	   been	   carefully	   investigated	   in	   epithelioid	   versus	  
sarcomatoid/biphasic	  MPM.	  
Our	   results	   showed	   that	   strong	   MDM2	   overexpression-­‐	   mainly	   in	   IHC-­‐	   was	  
significantly	  correlated	  with	  sarcomatoid/biphasic	  histotype	  even	   if	   the	  mRNA	  
levels	  of	  MDM2	  did	  not	  reach	  the	  statistically	  significant	  value.	  The	  correlation	  
test	  between	  mRNA	  and	  protein	  analysis	  was	  negative.	  These	  results	  might	  be	  
explained	   in	   different	   ways.	   First	   of	   all,	   literature	   data	   confirm	   that	   MDM2	  
protein	  overexpression	  is	  not	  only	  regulated	  by	  gene	  amplification,	  but	  also	  by	  
other	   mechanisms,	   such	   as	   transcriptional	   and	   post-­‐transcriptional	  
modifications[77].	   Secondarily,	   IHC	   detected	   only	   strong	   nuclear	   expression,	  
while	   RT-­‐qPCR	   quantified	   mRNA	   derived	   from	   the	   whole	   tumor	   sample.	  
Moreover,	   there	  are	  pools	  within	  a	   cell	  of	   active	  and	   inactive	  MDM2	   that	  do	  
not	   directly	   correlate	   with	   overall	   MDM2	   expression	   but	   which	   may	   reflect	  
different	   isoforms	   or	  modified	   forms	   of	   the	   protein.	  Moreover,	   other	   factors	  
could	   influence	   intracellular	  MDM2	   expression	   level	   such	   as	   altered	   rates	   of	  
transcription,	  mRNA	  stability,	  enhanced	  translation,	  and	  diminished	  destruction	  
of	   the	   protein	   all	   will	   affect	   intracellular	   levels	   of	   MDM2.	   The	   prognostic	  
significance	  of	  MDM2	  overexpression	  are	  quite	   controversial	   in	   the	   literature	  
[78].	   We	   found	   a	   trend	   towards	   a	   negative	   prognostic	   and	   predictive	  
significance	  of	  high	  MDM2	  strong	  nuclear	  expression	  levels.	  In	  our	  case	  series,	  
this	  lack	  of	  correlation	  with	  survival	  data	  may	  be	  related	  to	  several	  factors	  such	  
as	   the	   small	   sample	   size,	   especially	   for	   sarcomatoid/biphasic	   samples	   whose	  
	   58	  
survival	   data	   were	   available	   in	   a	   small	   number	   of	   patients;	   the	   insufficient	  
follow-­‐up	  time	  of	  the	  last	  patients	  might	  have	  some	  impact	  on	  prognosis.	  This	  
underlines	   the	   importance	   to	   validate	  our	   data	   in	   a	   prospective	   study	  with	   a	  
larger	   and	  more	   homogenous	   population.	   Our	   results	   reported	   a	   statistically	  
significant	   correlation	   of	   high	   Ki67	   levels	  with	   sarcomatoid/biphasic	   histology	  
and	   with	   high	   MDM2-­‐expressing	   tumors,	   and	   Ki67	   was	   the	   only	   covariate	  
significantly	  affecting	  progression	  free	  survival	  to	  the	  first	  line	  treatment,	  at	  the	  
multivariate	  analysis.	  	  
Thus,	  from	  our	  results,	   it	   is	  tempting	  to	  speculate	  that	  MDM2	  and	  Ki67	  might	  
be	   considered	   as	   important	   diagnostic	   parameters	   to	   characterize	  MPM	  with	  
poor	  prognosis.	  
Recently,	   nuclear	   grading	   in	   epithelioid	   mesothelioma	   has	   been	   shown	   as	   a	  
simple,	  practical,	  and	  cost-­‐effective	  prognostic	  tool	  that	  better	  stratifies	  clinical	  
outcome	   and	   time	   to	   recurrence	   than	   currently	   available	   clinicopathologic	  
factors	   [113].	   Our	   preliminar	   data	   on	   25	   epithelioid	   tumor	   samples	   where	  
survival	  data	  were	  available,	  showed	  only	  a	  trend	  towards	  a	  prognostic	  value	  of	  
nuclear	  grading,	  although	  not	   statistically	   significant,	  probably	  because	  of	   the	  
small	  sample	  size;	  in	  fact,	  we	  observed	  a	  median	  overall	  survival	  of	  128,	  96	  and	  
60	  weeks	  (p	  value=	  0.5),	  in	  those	  patients	  with	  G1	  (N=7),	  G2	  (N=9)	  and	  G3	  (N=9)	  
nuclear	  grading,	  respectively;	  median	  progression	  free	  survival	  was	  55,	  36	  and	  
58	  weeks	  (p=0.2),	  in	  patients	  with	  G1,	  G2	  and	  G3	  nuclear	  grading,	  respectively.	  
To	  date,	  no	  literature	  data	  are	  available	  about	  different	  levels	  of	  inflammation	  
and	   necrosis	   across	   mesothelioma	   histotypes;	   the	   prognostic	   significance	   of	  
necrosis	   in	  mesothelioma	   was	   reported	   by	   other	   groups,	   even	   though	   these	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results	  were	  limited	  to	  biphasic	  [87]	  or	  epithelioid	  histotype	  [114].	  Our	  results	  
did	   not	   show	   any	   significant	   difference,	   even	   though	   a	   trend	   towards	   higher	  
necrosis	   features	   in	   sarcomatoid/biphasic	   tumors	   was	   detected.	   This	   finding	  
may	   be	   due	   to	   a	   different	   biological	   behaviour	   of	   the	   two	   cancer	   types.	   The	  
sarcomatoid	  histotype	  would	  present	  necrosis	  following	  a	  failure	  blood	  supply,	  
as	  usually	  occurs	  in	  tumours	  with	  great	  proliferative	  index.	  
Overexpression	   of	   tumor	   neoangiogenesis	   markers	   has	   been	   previously	  
described	  as	  a	  prognostic	  factor	  in	  MPM	  patients,	  with	  particular	  reference	  to	  
VEGF	   [86,	   87].	   MDM2	   has	   been	   suggested	   as	   a	   possible	   regulator	   of	  
neoangiogenesis,	   both	   through	   direct	   regulation	   of	   VEGF	   and	   through	  
stabilization	  of	  HIF1alpha,	  responsible	  for	  VEGF	  transcription	  [95-­‐98].	  	  	  
Our	   results	   did	   not	   show	   significant	   difference	   of	   VEGF	   expression	   between	  
epithelioid	  and	  non-­‐epithelioid	  mesothelioma	  samples	  both	  at	  the	  protein	  and	  
mRNA	  level.	  These	  results,	  together	  with	  recent	  evidence	  from	  negative	  clinical	  
studies	  with	   Bevacizumab,	   a	  monoclonal	   antibody	   targeting	   VEGF,	   lead	   us	   to	  
leave	  the	  investigation	  of	  this	  marker	  in	  MPM.	  
One	   innovative	   finding	   of	   our	   study	   was	   the	   significant	   correlation	   between	  
HIF1alpha	  expression	   levels	   and	   the	   sarcomatoid/biphasic	  histotype,	   as	  much	  
as	  the	  correlation	  between	  expression	  levels	  of	  MDM2	  and	  HIF1alpha.	  
These	   results	   are	   of	   particular	   relevance	   further	   supporting	   the	   different	  
biological	   behaviour	   of	   sarcomatoid/biphasic	   versus	   epithelioid	   MPM.	   As	  
MDM2,	   HIF1alpha	   might	   be	   another	   promising	   target	   for	   antiangiogenetic	  
treatments	  in	  MPM	  because	  monoclonal	  antibodies	  against	  VEGF	  has	  failed	  in	  
the	   systemic	   treatment	   of	  mesothelioma.	   Further	   efforts	   should	   be	  made	   in	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order	   to	   clarify	   the	   role	   of	   other	   potential	   markers	   involved	   in	   the	   complex	  
process	  of	  neoangiogenesis.	  
7. Conclusion	  and	  summary	  of	  topic	  results	  
Our	  preclinical	  in	  vitro	  and	  in	  vivo	  results	  confirmed	  that	  reactivation	  of	  p53	  by	  
chemotherapy	  or	  p53-­‐MDM2	  inhibitors	  effectively	  promotes	  TRAIL-­‐dependent	  
apoptosis	  in	  malignant	  pleural	  mesothelioma:	  
-­‐	   rhApo2L/TRAIL	   combined	   to	   standard	   chemotherapy	   as	   first	   line	   treatment	  
and	   as	   single	   agent	   in	   the	   second	   line	   setting	  might	   prove	   to	   be	   an	   effective	  
drug	  in	  the	  treatment	  of	  MPM,	  considering	  also	  its	  low	  toxicity	  profile.	  	  
-­‐	   rhApo2L/TRAIL	   plus	   nutlin3-­‐RG7112	   showed	   remarkable	   anticancer	   effect,	  
expecially	  in	  the	  highly	  aggressive	  sarcomatoid	  models.	  
Our	   translational	   study	   in	   tumor	   samples	   from	   MPM	   patients	   confirmed	  
different	  biological	  and	  pathological	  features	  and	  molecular	  targets	  expression	  
in	  the	  two	  main	  histologic	  subtypes:	  
-­‐	   MDM2	   and	   HIF1alpha	   strong	   nuclear	   protein	   expression	   and	   proliferation	  
index	  are	  higher	  in	  sarcomatoid/biphasic	  samples.	  Proliferation	  index	  is	  higher	  
in	   sarcomatoid	   and	   MDM2-­‐overexpressing	   samples,	   and	   higher	   Ki67	   levels	  
correlate	  with	  shorter	  progression	  free	  survival.	  
From	   our	   results,	   it	   is	   tempting	   to	   speculate	   that	  MDM2	   and	   Ki67	  might	   be	  
considered	  interesting	  markers	  to	  characterize	  MPM	  with	  poor	  prognosis.	  
-­‐	   For	   the	   first	   time,	   our	   study	   showed	   a	   significant	   correlation	   between	  
expression	   levels	   of	   MDM2	   and	   HIF1alpha.	   This	   has	   relevant	   therapeutic	  
implications	  expecially	  for	  possible	  targeted	  therapies	  aimed	  to	  the	  use	  of	  new	  
antiangiogenetic	  and	  proapoptotic	  treatments.	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8. Appendix:	  figures	  and	  tables	  
	  
Figure	  1a.	  Anticancer	  effects	  of	  rhAPO2L/tumor	  necrosis	  factor-­‐related,	  
apoptosis-­‐inducing	  ligand	  (TRAIL)	  in	  malignant	  pleural	  mesothelioma	  (MPM)	  
cell	  lines	  and	  primary	  culture.	  MPM	  cell	  lines	  and	  control	  cells	  (human	  foreskin	  
fibroblasts	  and	  peripheral	  blood	  mononuclear	  cells)	  were	  treated	  
with	  rhAPO2L/TRAIL	  (T)	  50	  ng/ml	  for	  24	  hours	  and	  Annexin	  V	  staining	  was	  
evaluated.	  Results	  were	  represented	  as	  mean	  ±	  SE	  of	  three	  different	  
experiments	  running	  in	  duplicate.	  *Statistically	  significant	  difference	  of	  specific	  
apoptosis	  between	  MPM	  cells	  treated	  with	  rhAPO2L/TRAIL	  compared	  with	  




Figure	  1b.	  Anticancer	  effects	  of	  rhAPO2L/TRAIL	  in	  MPM	  cell	  lines	  and	  primary	  

















































































































































































Figure	  2a	  and	  2b	  
ZL55	  and	  ZL34	  cell	  lines	  were	  previously	  treated	  with	  Carboplatin	  plus	  
Pemetrexed	  (CP)	  for	  24	  hours	  followed	  by	  rhAPO2L/TRAIL	  (T)	  50	  ng/ml	  for	  24	  
hours	  and	  apoptosis	  induction	  was	  evaluated	  by	  AnnexinV/PI	  staining	  (2a)	  and	  
caspases	  assay	  (2b).	  Mean	  of	  Specific	  Apoptosis	  ±	  SE	  of	  three	  independent	  
experiments	  running	  in	  triplicate	  are	  given.*statistically	  significant	  difference	  of	  
Specific	  Apoptosis	  and	  specific	  caspases	  activity	  between	  MPM	  cells	  treated	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Figure	  2c	  
ZL55	  and	  ZL34	  cell	  lines	  were	  treated	  with	  different	  concentration	  of	  
Carboplatin/Pemetrexed	  (in	  constant	  ratios)	  and	  rhAPO2L/TRAIL.	  The	  
synergistic	  apoptosis	  induction	  of	  the	  combinations	  was	  calculated	  using	  the	  CI	  
methods	  and	  represented	  as	  the	  mean	  of	  CI	  values	  at	  FA	  (fraction	  affected)	  
0.25,	  0.5,	  0.75	  and	  0.9.	  Results	  were	  represented	  as	  mean	  ±	  SE	  of	  three	  different	  




MPM	  cell	  lines	  were	  treated	  with	  Nutlin3a	  (NUTL)	  10uM	  and	  Apo2L/TRAIL	  (T)	  
50ng/ml	  for	  24	  hours	  and	  analyzed	  by	  AnnexinV	  staining.	  Specific	  Apoptosis	  
was	  calculated	  by	  the	  following	  formula:	  (percentage	  of	  Annexin	  V	  positive	  cells	  
in	  treated	  samples-­‐	  percentage	  of	  Annexin	  V	  positive	  cells	  in	  untreated	  samples)	  
/	  (100-­‐	  percentage	  of	  Annexin	  V	  positive	  cells	  in	  untreated	  samples)*100.	  The	  
results	  were	  represented	  as	  means	  ±	  SE	  of	  3	  different	  experiments	  running	  in	  
triplicate.*	  statistically	  significant	  difference	  of	  Specific	  Apoptosis	  between	  cells	  
treated	  with	  NUTL+T	  compared	  with	  cells	  treated	  with	  T	  (p<	  0.05)	  (Mann-­‐
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Figure	  3	  
MPM	  cell	  lines	  were	  previously	  treated	  with	  Carboplatin	  plus	  Pemetrexed	  (CP)	  
for	  24	  hours	  followed	  by	  rhAPO2L/TRAIL	  (T)	  for	  24	  hours	  and	  Specific	  Apoptosis	  
was	  detected	  by	  Annexin	  V	  staining.	  Results	  were	  represented	  as	  mean	  ±	  SE	  of	  
three	  different	  experiments	  running	  in	  duplicate.	  
*statistically	  significant	  difference	  of	  Specific	  Apoptosis	  between	  MPM	  cells	  






MPM	  cells	  were	  previously	  incubated	  with	  100	  uM	  NAC	  overnight	  and	  then	  
treated	  or	  not	  (NT)	  with	  Carboplatin/Pemetrexed	  (CP)	  and/or	  rhAPO2L/TRAIL	  
(T).	  Specific	  Apoptosis	  was	  detected	  by	  Annexin	  V	  staining.	  Results	  were	  
represented	  as	  mean	  ±	  SE	  of	  three	  different	  experiments	  running	  in	  duplicate	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Figure	  5a	  
Western	  blot	  analysis	  of	  p53	  protein	  expression	  levels	  in	  ZL55	  and	  ZL34	  cell	  lines	  
treated	  or	  not	  with	  CP	  for	  24	  hours.	  Where	  indicated,	  cells	  were	  previously	  





MPM	  cell	  lines	  were	  treated	  with	  scrbl	  or	  siRNA-­‐p53	  (25	  nM)	  in	  presence	  or	  not	  
of	  wild-­‐type	  p53	  vector	  (200	  ng)	  for	  24	  hours	  followed	  by	  CP	  stimulation	  and	  
western	  blot	  analysis	  of	  p53	  protein	  expression	  levels	  was	  performed	  (left	  
panel).	  Western	  blot	  analysis	  of	  p53	  protein	  expression	  levels	  in	  tissue	  
specimens	  of	  5	  MPM	  patients	  (right	  panel).	  We	  were	  unable	  to	  detect	  proteins	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Figure	  5c	  
MPM	  cell	  lines	  were	  treated	  with	  scrbl	  or	  siRNA-­‐p53	  (25	  nM)	  in	  presence	  or	  not	  of	  wild-­‐
type	  p53	  vector	  (200	  ng)	  for	  24	  hours	  followed	  by	  CP	  and/or	  T	  stimulation	  and	  Annexin	  
V/PI	  assay	  was	  performed.	  Results	  were	  represented	  as	  mean	  ±	  SE	  of	  three	  different	  
experiments	  running	  in	  duplicate.	  *statistically	  significant	  difference	  of	  Specific	  
Apoptosis	  between	  MPM	  cells	  treated	  with	  scrbl	  plus	  CPT	  compared	  with	  cells	  treated	  





Flow	  cytometry	  analysis	  of	  TRAIL-­‐Receptors	  expression	  levels	  in	  ZL55	  and	  ZL34	  cell	  lines	  
treated	  with	  Carboplatin/Pemetrexed	  (CP)	  for	  24	  hours.	  The	  graph	  bar	  represents	  the	  
mean	  of	  relative	  expression	  of	  TRAIL-­‐R	  (for	  DR4	  and	  DR5)	  ±	  SE	  of	  three	  independent	  
experiments	  running	  in	  triplicate.	  *	  statistically	  significant	  difference	  of	  receptor	  
expression	  levels	  between	  MPM	  cells	  untreated	  (NT)	  compared	  to	  MPM	  cells	  treated	  










ZL34	  cell	  lines	  were	  treated	  with	  NUTL	  10uM	  for	  24	  hours:	  A)	  Flow	  cytometry	  analysis	  
of	  DR4/DR5	  TRAIL-­‐Receptors	  expression	  levels.	  Relative	  expression	  of	  TRAIL-­‐R	  was	  
calculated	  by	  the	  following	  formula:	  percentage	  of	  positive	  cells	  x	  mean	  fluorescence	  
intensity	  (MFI).	  The	  graph	  bar	  represents	  the	  mean	  of	  relative	  expression	  of	  TRAILR	  ±	  
SE	  of	  three	  independent	  experiments	  running	  in	  triplicate.	  *	  statistically	  significant	  
difference	  of	  receptor	  expression	  levels	  between	  MPM	  cells	  untreated	  (NT)	  compared	  
to	  MPM	  cells	  treated	  with	  NUTL	  (p<	  0.05)	  (Mann-­‐Whitney	  test).	  B)	  Western	  blot	  





Flow	  cytometry	  analysis	  of	  TRAIL-­‐Receptors	  expression	  levels	  in	  ZL55	  and	  ZL34	  cell	  lines	  
treated	  with	  negative	  control	  scrambled	  sequence	  (scrbl)	  or	  siRNA-­‐p53	  (25	  nM)	  in	  
presence	  or	  not	  of	  wild-­‐type	  p53	  vector	  (200	  ng)	  for	  24	  hours	  followed	  by	  CP	  treatment.	  
A)	  Representative	  dot	  blot	  representing	  MPM	  cells	  treated	  with	  scrbl	  plus	  CP	  versus	  
siRNA-­‐p53	  plus	  CP.	  p≤	  0.001	  indicate	  differences	  in	  fluorescence	  by	  Kolmogorov-­‐
Smirnov	  Statistics.	  B)	  The	  results	  were	  represented	  as	  mean	  of	  relative	  expression	  of	  
TRAIL-­‐R	  ±	  SE	  of	  three	  different	  experiments	  running	  in	  duplicate.	  *	  statistically	  
significant	  difference	  of	  receptor	  expression	  levels	  between	  MPM	  cells	  treated	  with	  
scrbl	  plus	  CP	  compared	  to	  MPM	  cells	  treated	  with	  siRNA-­‐p53	  plus	  CP	  (p<	  0.05)	  by	  
Mann-­‐Whitney	  test.	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Figure	  8a	  and	  8b	  
Mice	  were	  subcutaneously	  injected	  with	  2x106	  of	  ZL55	  (8a,	  upper	  graph	  )	  or	  ZL34	  (8b,	  
lower	  graph)	  cell	  lines	  and	  randomized	  in	  four	  treatment	  groups	  (n=6/group).	  When	  
tumor	  volumes	  reached	  50mm3	  (day	  1),	  each	  group	  received	  by	  intraperitoneal	  
injection	  vehicle	  or	  Carboplatin/Pemetrexed	  (CP)	  (on	  day	  1)	  or	  rhAPO2L/TRAIL	  
(Dulanermin,	  DUL)	  (on	  days	  1,2,3)	  or	  CP+DUL	  (on	  day	  1	  and	  days	  1,2,3	  respectively).	  
Tumor	  volumes	  were	  recorded	  every	  third	  day.	  The	  results	  were	  represented	  as	  mean	  
of	  delta	  volume	  ±	  SD.	  *	  statistically	  significant	  difference	  of	  delta	  tumor	  volume	  
between	  treated	  groups	  and	  untreated	  controls	  (p<0.05).	  §	  statistically	  significant	  
difference	  of	  delta	  tumor	  volume	  between	  CPT	  and	  CP	  	  (p<0.05)	  by	  analysis	  of	  variance	  
(ANOVA)	  followed	  by	  LSD	  post	  hoc	  test.	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Figure	  9	  
Mice	  were	  intraperitoneally	  (IP)	  injected	  with	  5x106	  ZL34	  cells	  previously	  transduced	  
with	  lentiviral	  vector	  containing	  a	  plasmid	  encoding	  for	  Luciferase.	  3	  weeks	  post	  
injection	  the	  mice	  were	  randomized	  in	  4	  treatment	  groups	  	  and	  treated	  with	  Nutlin3	  3a	  
or	  vehicle	  (days	  1-­‐21)	  by	  gavage	  and/or	  APO2L/TRAIL	  (days	  1-­‐3)	  by	  IP.	  Tumor	  size	  was	  
assessed	  at	  the	  indicated	  time	  point	  by	  in	  vivo	  bioluminescence	  using	  Xenogen	  
bioluminescence	  imaging	  after	  IP	  injection	  of	  D-­‐luciferin	  in	  each	  mouse.	  The	  mice	  were	  
suppressed	  at	  the	  22th	  day.	  Average	  Radiance	  [p/s/cm²/sr]	  was	  proportional	  to	  the	  
number	  of	  ZL34	  cells	  expressing	  the	  LUC	  gene	  and	  D	  Average	  radiance	  was	  used	  as	  
indicator	  of	  tumor	  growth	  and	  calculated	  by	  the	  following	  formula:	  (Average	  Radiance	  
at	  the	  day	  n-­‐	  Average	  Radiance	  at	  the	  day	  1)/Average	  radiance	  at	  the	  day	  1	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Figure	  11.	  HIF1alpha	  expression	  levels	  in	  epithelioid	  versus	  sarcomatoid/biphasic	  
samples.	  
	  
	   71	  















Figure	  12.	  Inflammation	  (a),	  necrosis	  (b)	  and	  proliferation	  index	  (c)	  in	  epithelioid	  versus	  
sarcomatoid/biphasic	  samples	  (d).	  
E:epithelioid;	  S/B:	  sarcomatoid/biphasic;	  *	  statistically	  significant	  
	  
	  
	   	  





Figure	  13.	  Overall	  survival	  (a)	  and	  Progression	  Free	  Survival	  (b)	  in	  epithelioid	  versus	  












Figure	  14.	  Overall	  survival	  (a)	  and	  Progression	  Free	  Survival	  (b)	  in	  low	  MDM2	  versus	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Figure	  15.	  mRNA	  MDM2	  expression	  levels	  in	  epithelioid	  versus	  sarcomatoid	  
mesothelioma	  cell	  lines.	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Table	  5.	  Inflammation,	  necrosis	  and	  proliferation	  index	  across	  tumor	  samples.	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  Medical	  Oncology	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  Oncologist	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   Molecular	  Oncology	  laboratories,	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  oncological	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  research	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  Medical	  Oncology	  Unit,	  Istituto	  Oncologico	  
Veneto	  
Padua	  (Italy)	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  of	  business	  or	  sector	   Medical	  Oncology	  
Dates	   01/01/2006	  -­‐	  30/06/2007	  	  
Occupation	  or	  position	  held	   Resident	  in	  Medical	  Oncology	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  and	  translational	  research	  in	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  address	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  and	  Surgical	  Science	  Department,	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  Section,	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  of	  Padua	  (Italy)	  
Type	  of	  business	  or	  sector	   Molecular	  Oncology	  
Education	  and	  Training	   	  
Dates	   01/01/2012-­‐currently	  ongoing	  	  
Title	  of	  qualification	  awarded	   PhD	  
Principal	  subjects/occupational	  
skills	  covered	  	  
Neoangiogenic	  biomarkers	  and	  therapeutic	  targets	  	  
in	  malignant	  pleural	  mesothelioma	  	  
Dates	   01/01/2006	  -­‐	  31/12/2010	  	  




Name	  and	  type	  of	  organisation	  
providing	  education	  and	  training	  
Residency	  School	  in	  Medical	  Oncology	  	  
(University	  of	  Padua)	  Padua	  (Italy)	  
Dates	   01/10/1999	  -­‐	  11/10/2005	  	  
Title	  of	  qualification	  awarded	   Graduation	  in	  medicine	  and	  surgery	  	  
Name	  and	  type	  of	  organisation	  
providing	  education	  and	  training	  
	  	  	  	  	  	  	  	  	  	  	  	  	  Other	  training	  experiences	  
University	  of	  Ferrara	  (Ferrara,	  Italy)	  
	  	  
March	  2014:	  admitted	  at	  the	  13th	  ESO	  ESMO	  	  
Masterclass	  in	  Clinical	  Oncology	  where	  she	  attended	  
plenary	  lectures	  regarding	  state-­‐of-­‐the-­‐art	  clinical	  
evaluation	  and	  treatments	  in	  oncology.	  As	  a	  selected	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participant	  the	  applicant	  presented	  a	  research	  	  
abstract	  which	  was	  selected	  for	  publication	  and	  	  
had	  the	  opportunity	  to	  present	  and	  discuss	  with	  the	  
faculty	  clinical	  cases	  of	  thoracic	  cancer.	  
Personal	  skills	  and	  competences	   	  
Mother	  tongue(s)	   Italian	  
Other	  language(s)	   English:	  excellent	  reading,	  writing,	  speaking	  
Organisational	  skills	  and	  
competences	  
Additional	  informations	  
Clinical	  and	  translational	  research	  projects	  design	  and	  
conduction.	  
	  
-­‐	  2010-­‐2011:	  recipient	  of	  ESMO	  (European	  Society	  for	  
Medical	  Oncology)	  translational	  research	  fellowship	  
award	  	  
-­‐	  2012:	  recipient	  of	  IMIG	  (International	  Mesothelioma	  
Interest	  group)	  travel	  award	  	  
-­‐2014	  ‘Saro	  Leggio’	  award	  for	  translational	  study	  of	  
malignant	  pleural	  mesothelioma	  
-­‐	  2011-­‐	  current	  position:	  National	  AIOM	  (Assicioazione	  
Italiana	  di	  Oncologia	  Medica)	  young	  working	  group	  
elected	  member	  	  
-­‐	  Since	  January	  2014	  she	  is	  lecturer	  at	  the	  fith	  year	  of	  
Specialization	  School	  of	  Medical	  Oncology	  with	  the	  
teaching	  ‘Epidemiology,	  diagnosis	  and	  staging	  of	  
neuroendocrine	  tumors’,	  and	  supervisor	  of	  several	  
students	  attending	  the	  Specialization	  School	  in	  Medical	  
Oncology	  
Participation	  as	  a	  speaker	  and	  scientiific	  committee	  to	  
several	  national	  conferences	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Summary	  of	  scientific	  and	  research	  activity	  
Several	  research	  and	  scientific	  activities	  have	  been	  done	  during	  the	  three	  years	  of	  PhD	  
program.	  First,	  the	  scientific	  literature	  study	  about	  the	  main	  object	  of	  the	  project	  –
malignant	  pleural	  mesothelioma-­‐	  lead	  to	  the	  study	  design	  which	  took	  into	  account	  the	  
main	  unmet	  medical	  needs	  and	  scientific	  questions	  in	  the	  specific	  context.	  
After	  study	  design	  and	  planning	  and	  working	  group	  constitution,	  a	  grant	  application	  
was	  performed	  in	  order	  to	  receive	  support	  for	  preclinical	  and	  traslational	  studies.	  The	  
European	  Society	  for	  Medical	  Oncology	  (ESMO)	  translational	  research	  fellowship	  
award	  was	  received	  in	  2012	  and	  renewed	  also	  for	  the	  second	  year.	  The	  project	  was	  
mainly	  divided	  into	  two	  aims.	  Preclinical	  studies	  about	  new	  drug	  combinations	  for	  the	  
treatment	  of	  the	  disease	  under	  study	  were	  performed	  during	  the	  first	  two	  years,	  while	  
the	  third	  year	  was	  focused	  on	  translational	  studies	  investigating	  treatment	  targets	  and	  
morphological	  features	  on	  patients	  samples.	  In	  July	  2014	  the	  first	  paper	  reporting	  data	  
from	  this	  project	  was	  published,	  and	  currently	  two	  more	  papers	  are	  under	  review.	  
Malignant	  mesothelioma	  was	  the	  main	  field	  of	  interest	  during	  the	  three	  years	  of	  the	  
PhD	  program,	  both	  as	  clinical	  management	  and	  research	  studies,	  and	  several	  papers	  
were	  published	  as	  single-­‐center	  thoracic	  oncology	  group	  and	  in	  collaboration	  with	  
other	  specialized	  center.	  
Scientific	  publication	  with	  impact	  factor	  (2012-­‐2014)	  
1°	  year	  
-­‐	  Gridelli	  C,	  Gallo	  C,	  Morabito	  A,	  Iaffaioli	  RV,	  Favaretto	  A,	  Isa	  L,	  Barbera	  S,	  Gamucci	  T,	  
Ceribelli	  A,	  Filipazzi	  V,	  Maione	  P,	  Rossi	  A,	  Barletta	  E,	  Signoriello	  S,	  De	  Maio	  E,	  Piccirillo	  
MC,	  Di	  Maio	  M,	  Rocco	  G,	  Vecchione	  A,	  Perrone	  F;	  G-­‐STEP	  Investigators	  “Phase	  I-­‐II	  trial	  
of	  gemcitabine-­‐based	  first-­‐line	  chemotherapies	  for	  small	  cell	  lung	  cancer	  in	  elderly	  
	   100	  
patients	  with	  performance	  status	  0-­‐2:	  the	  G-­‐STEP	  trial”	  J	  Thorac	  Oncol.	  2012	  
Jan;7(1):233-­‐42	   	   	   	   	   	   	   	  
-­‐	  Di	  Maio	  M,	  Leighl	  NB,	  Gallo	  C,	  Feld	  R,	  Ciardiello	  F,	  Butts	  C,	  Maione	  P,	  Gebbia	  V,	  
Morgillo	  F,	  Wierzbicki	  R,	  Favaretto	  A,	  Alam	  Y,	  Cinieri	  S,	  Siena	  S,	  Bianco	  R,	  Riccardi	  F,	  
Spatafora	  M,	  Ravaioli	  A,	  Felletti	  R,	  Fregoni	  V,	  Genestreti	  G,	  Rossi	  A,	  Mancuso	  G,	  Fasano	  
M,	  Morabito	  A,	  Tsao	  MS,	  Signoriello	  S,	  Perrone	  F,	  Gridelli	  C;	  TORCH	  
Investigators.“Quality	  of	  life	  analysis	  of	  TORCH,	  a	  randomized	  trial	  testing	  first-­‐line	  
erlotinib	  followed	  by	  second-­‐line	  cisplatin/gemcitabine	  chemotherapy	  in	  advanced	  
non-­‐small-­‐cell	  lung	  cancer.”	  J	  Thorac	  Oncol.	  2012	  Dec;7	  (12):1830-­‐4	   	   	   	  
-­‐	  Pasello	  G,	  Marulli	  G,	  Polo	  V,	  Breda	  C,	  Bonanno	  L,	  Loreggian	  L,	  Rea	  F,	  Favaretto	  A.	  
“Pemetrexed	  plus	  carboplatin	  or	  cisplatin	  as	  neoadjuvant	  treatment	  of	  operable	  
malignant	  pleural	  mesothelioma	  (MPM)”	  Anticancer	  Res.	  2012	  Dec;32	  (12):5393-­‐9.	   	  
2°	  year	  
-­‐	  Pasello	  G,	  Ceresoli	  GL,	  Favaretto	  A	  “An	  overview	  of	  neoadjuvant	  chemotherapy	  in	  the	  
multimodality	  treatment	  of	  malignant	  pleural	  mesotelioma”.	  Cancer	  Treat	  Rev.	  2013	  
Feb;39	  (1):10-­‐7	  
-­‐	  Marulli	  G,	  Di	  Chiara	  F,	  Braccioni	  F,	  Perissinotto	  E,	  Pasello	  G,	  Gino	  Favaretto	  A,	  Breda	  
C,	  Rea	  F.	  “Changes	  in	  pulmonary	  function	  tests	  predict	  radiological	  response	  to	  
chemotherapy	  in	  malignant	  pleural	  mesothelioma”	  Eur	  J	  Cardiothorac	  Surg.	  2013	  Jul;	  
44	  (1):104-­‐10	  
-­‐Pasello	  G,	  Urso	  L,	  Conte	  P,	  Favaretto	  A.	  “Effects	  of	  Sulfonylureas	  on	  Tumor	  Growth:	  A	  
Review	  of	  the	  Literature”.	  Oncologist.	  2013;18(10):1118-­‐25	  
3°	  year	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-­‐	  Pasello	  G,	  Urso	  L,	  Silic-­‐Benussi	  M,	  Schiavon	  M,	  Cavallari	  I,	  Marulli	  G,	  Nannini	  N,	  Rea	  F,	  
Ciminale	  V,	  Favaretto	  A.	  “Synergistic	  antitumor	  activity	  of	  recombinant	  human	  
Apo2L/tumor	  necrosis	  factor-­‐related	  apoptosis-­‐inducing	  ligand	  (TRAIL)	  in	  combination	  
with	  carboplatin	  and	  pemetrexed	  in	  malignant	  pleural	  mesothelioma.”J	  Thorac	  Oncol.	  
2014	  Jul;9(7):1008-­‐17.	  	  
-­‐	  Ceresoli	  GL,	  Grosso	  F,	  Zucali	  PA,	  Mencoboni	  M,	  Pasello	  G,	  Ripa	  C,	  Degiovanni	  D,	  
Simonelli	  M,	  Bruzzone	  A,	  Dipietrantonj	  C,	  Piccolini	  E,	  Beretta	  GD,	  Favaretto	  AG,	  
Giordano	  L,	  Santoro	  A,	  Botta	  M.“Prognostic	  factors	  in	  elderly	  patients	  with	  malignant	  
pleural	  mesothelioma:	  results	  of	  a	  multicenter	  survey.”Br	  J	  Cancer.	  2014	  Jul	  
15;111(2):220-­‐6.	  	  
-­‐	  Marulli	  G,	  Verderi	  E,	  Zuin	  A,	  Schiavon	  M,	  Battistella	  L,	  Perissinotto	  E,	  Romanello	  P,	  
Favaretto	  AG,	  Pasello	  G,	  Rea	  F.”Outcomes	  and	  prognostic	  factors	  of	  non-­‐small-­‐cell	  lung	  
cancer	  with	  lymph	  node	  involvement	  treated	  with	  induction	  treatment	  and	  surgical	  
resection.”Interact	  Cardiovasc	  Thorac	  Surg.	  2014	  Aug;19(2):256-­‐62	  
-­‐	  Schiavon	  M,	  Marulli	  G,	  Nannini	  N,	  Pasello	  G,	  Lunardi	  F,	  Balestro	  E,	  Perissinotto	  E,	  
Rebusso	  A,	  Saetta	  M,	  Rea	  F,	  Calabrese	  F.	  “COPD-­‐related	  adenocarcinoma	  presents	  low	  
aggressiveness	  morphological	  and	  molecular	  features	  compared	  to	  smoker	  tumours”.	  
Lung	  Cancer.	  2014	  Dec;	  86(3):311-­‐7.	  
-­‐	  Pasello	  G,	  Carli	  P,	  Canova	  F,	  Bonanno	  L,	  Polo	  V,	  Zago	  G,	  Urso	  L,	  Conte	  PF,	  Favaretto	  A.	  
“Epirubicin	  plus	  Paclitaxel	  regimen	  as	  second	  line	  treatment	  of	  Small-­‐Cell	  Lung	  Cancer	  
(SCLC)	  patients”	  IN	  PRESS	  
Book	  chapter	  (2012-­‐2014)	  
-­‐	  	  Giulia	  Pasello	  and	  Adolfo	  Favaretto.	  Neoadjuvant	  Chemotherapy	  in	  Malignant	  Pleural	  
Mesothelioma.	  Malignant	  Mesothelioma	  Chapter	  5	  December	  2012.	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http://dx.doi.org/10.5772/47880	  
-­‐	  Giovanni	  Luca	  Ceresoli,	  	  Giulia	  Pasello,	  Fiorella	  Calabrese.	  
ESMO	  book:	  Thoracic	  Tumours	  –Essentials	  for	  Clinicians:	  Malignant	  Pleural	  
Mesothelioma	  
March	  2014	  
Conference	  participation	  (2012-­‐2014)	  
-­‐advances	  in	  medicine	  23	  march	  2012,	  Padova	  
-­‐	  2012	  american	  society	  of	  clinical	  oncology	  (asco)	  meeting	  1-­‐5	  june	  2012,	  Chicago	  (il)	  
-­‐	  primo	  congresso	  italo-­‐greco	  di	  oncologia	  medica,	  Padova,	  10-­‐11	  may	  2012:	  
“treatment	  of	  malignant	  pleural	  mesothelioma:	  multimodality	  management	  and	  new	  
perspectives”	  (speaker)	  
-­‐aiom	  post	  asco	  review:	  updates	  and	  news	  from	  the	  annual	  meeting	  in	  chicago,	  
Bologna	  16-­‐17	  june	  2012:	  “lung	  cancer:	  asco	  poster	  review”	  (speaker)	  
-­‐	  endothelial	  progenitors	  cells	  from	  discovery	  to	  therapy	  21	  june	  2012,	  Padova	  
-­‐	  hot	  topics	  in	  oncologia	  toracica:	  stato	  dell’arte	  sulla	  terapia	  medica	  del	  mesotelioma	  
pleurico,	  Bergamo	  22	  june	  2012	  (speaker)	  
-­‐	  the	  11th	  international	  mesothelioma	  interest	  group	  (imig)	  conference	  11-­‐14	  
september	  2012,	  Boston	  (ma)	  (speaker)	  
-­‐	  malignant	  pleural	  mesothelioma:	  clinical	  pathological	  and	  legal	  features	  8	  november	  
2012,	  Padova(speaker)	  
-­‐	  corso	  nibit:	  immunobioterapia	  nelle	  neoplasie	  toraciche,	  Padova	  23	  november	  2012	  
(speaker)	  
-­‐	  xii	  congresso	  nazionale	  fonicap	  (forza	  operativa	  nazionale	  interdisciplinare	  contro	  il	  
cancro	  al	  polmone),	  Verona	  30	  november-­‐1	  december	  2012	  (speaker)	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-­‐	  corso	  nazionale	  aiom	  e	  siapec-­‐iap	  “marcatori	  biomolecolari	  nella	  terapia	  
personalizzata	  dei	  tumori:	  indicazioni	  cliniche	  e	  di	  laboratorio”,	  Napoli	  22	  march	  2013	  
-­‐	  “antiangiogenic	  therapy:	  recent	  advances	  and	  future	  directions	  in	  oncology”,	  Padova	  
23	  april	  2013	  
-­‐	  corso	  educazionale	  macroregionale	  aiom	  giovani	  “metodologia	  della	  ricerca	  clinica	  in	  
oncologia”,	  Verona	  3-­‐4	  may	  2013	  (speaker)	  
-­‐	  convegno	  aiom	  giovani	  veneto:	  “tumori	  rari:	  tra	  empirismo	  ed	  evidenza”,	  Padova	  21	  
june	  2013	  (speaker)	  
-­‐	  convegno	  nazionale	  aiom	  giovani	  “news	  in	  oncology	  2013”,	  Perugia	  5-­‐6	  july	  2013	  
(speaker)	  
-­‐	  corso	  di	  formazione	  del	  personale	  medico	  in	  oncologia	  generale,	  Bugando	  medical	  
centre,	  Mwanza,	  Tanzania,	  30	  september	  2013	  –	  04	  october	  2013	  (speaker)	  
-­‐	  congresso	  fonicap	  le	  terapie	  biologichenel	  nsclc:	  update	  dopo	  iaslc	  2013,	  Verona	  9	  
december	  2013	  (speaker)	  
-­‐	  2014	  esmo-­‐christie	  lung	  cancer	  course,	  manchester	  (uk)	  12-­‐14	  february	  2014	  
-­‐13th	  eso-­‐esmo	  masterclass	  in	  clinical	  oncology,	  8	  march	  2014-­‐13	  march	  2014,	  
Ermatingen	  Switzerland	  
-­‐	  hot	  topics	  in	  oncologia	  toracica:il	  mesotelioma	  pleurico,	  Bergamo	  24	  may	  2014	  
(speaker)	  
-­‐	  aiom	  post-­‐asco	  2014,	  Bologna	  13-­‐14	  june	  2014	  (speaker)	  
-­‐	  convegno	  nazionale	  aiom	  giovani	  “news	  in	  oncology	  2014”,	  Perugia	  11-­‐12	  july	  2014	  
(speaker)	  
-­‐	  2014	  esmo	  meeting,	  Madrid	  26	  september	  2014-­‐	  30	  september	  2014	  (poster	  
presenter)	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-­‐	  chest	  tumors:	  what’s	  new	  from	  asco-­‐esmo	  meetings?	  Padova	  9-­‐10	  october	  2014	  
(speaker)	  
-­‐	  the	  12th	  international	  mesothelioma	  interest	  group	  (imig)	  conference	  21	  october	  
2014-­‐24	  october	  2014	  Cape	  Town	  Africa	  (poster	  presenter)	  
-­‐	  corso	  macroregionale	  aiom	  di	  metodologia	  della	  ricerca,	  Torino	  7-­‐8	  november	  2014	  
(speaker)	  
Awards	  and	  grants:	  
- 2010-­‐2011	  and	  2011-­‐2012:	  recipient	  of	  ESMO	  (European	  Society	  for	  Medical	  
Oncology)	  translational	  research	  fellowship	  award	  
- 2012:	  recipient	  of	  IMIG	  (International	  Mesothelioma	  Interest	  group)	  travel	  
award	  
- 2014:	  premio	  per	  la	  ricerca	  ‘Saro	  Leggio’	  (AIRPP)	  
Teaching	  activity	  
- professor	  with	  contract	  5°	  year	  of	  residency	  school	  in	  medical	  oncology	  with	  
the	  teaching:	  epidemiology,	  diagnosis	  and	  staging	  	  of	  neuroendocrin	  tumors	  
Research	  activity	  
- -­‐Coinvestigator	  of	  more	  than	  30	  clinical	  trials	  on	  lung	  cancer,	  pleural	  
mesothelioma	  and	  thymic	  cancer	  	  
- Principal	  investigator	  of	  preclinical	  studies	  on	  the	  anticancer	  activity	  of	  new	  
drugs	  combinations	  in	  malignant	  pleural	  mesothelioma.	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Thanks	  to:	  
The	  present	  research	  project	  is	  the	  result	  of	  a	  multidisciplinary	  team	  involved	  in	  
basic,	  translational	  and	  clinical	  research	  and	  medical	  management	  of	  thoracic	  
tumors.	  	  
With	  particular	  respect	  and	  gratitude,	  I	  would	  like	  to	  thank:	  
	  
Prof.	  Federico	  Rea,	  Prof.	  Fiorella	  Calabrese	  
Department	  of	  Cardiac,	  Thoracic	  and	  Vascular	  Sciences	  (University	  of	  Padova)	  
	  
Dr.	  Adolfo	  Favaretto	  and	  Dr.	  Vincenzo	  Ciminale	  	  
Istituto	  Oncologico	  Veneto	  
	  
Dr.	  Loredana	  Urso	  
Department	  of	  Surgical,	  Oncological	  and	  Gastroenterological	  Sciences	  
(University	  of	  Padova)	  
	  
	  
	  
	  
	  
	  
	  
	  
